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Interferon gamma release assays (IGRAs) are regarded as an alternative measure to the 
tuberculin skin test (TST) of latent tuberculosis infection (LTBI) and have been recommended 
for serial testing in populations with a continued risk of tuberculosis exposure. However 
evidence is still lacking on several key questions that include defining IGRA conversion and its 
predictive value for the development of tuberculosis disease.  
 
As an extension of a prospective epidemiological study of TB disease and infection in 
adolescents in the Worcester and surrounding areas in the Western Cape carried out from 2005 
to 2009, a subset of adolescents who were identified to have converted their IGRA status were 
followed up and observed for the occurrence of active TB disease over a further period of two 
years and compared to non-converters. A known risk of developing active TB disease is 
associated with TST conversions. This risk in those who have converted their IGRA 
(QuantiFERON) status is unknown.  
 
The Protocol (Part A) of this dissertation outlines the study design and methodology used in 
the conduct of the research study. The Literature Review (Part B) aims to contextualize this 
study by examining the available literature on the role of the TST in diagnosing TB and how 
IGRAs compare to the TST, the interpretation of serial IGRA data with a focus on IGRA 
conversion, the prognosis of an IGRA conversion and its potential use as a predictive test for 
the development of active TB disease. The Manuscript (Part C) presents the results of the 
study. The main objectives were to evaluate the incidence rate of active tuberculosis disease 
following QuantiFERON Gold In-Tube (QFT-IT) conversion and to assess its predictive value 
for the development of tuberculosis disease. The results show that QFT conversion is indicative 
of an approximately 7-fold higher risk of progression to TB disease (compared to non-
converters). The predictive value of QFT conversion for the development of active TB disease is 
2.4% within 2 years following QFT conversion. Further studies in high and low TB burden 
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1. PROTOCOL SYNOPSIS 
Title: The Predictive Value of a QuantiFERON Conversion in the development of Active      
Tuberculosis Disease in Adolescents. 
Rationale: With tuberculosis (TB) accounting for nine million new cases of TB and 1.8 million 
deaths reported in 2007, it is amongst the world’s most lethal infectious agents causing more 
adult deaths than any other pathogen. TB has been declared a global health emergency by the 
World Health Organisation (WHO). Mycobacterium tuberculosis (Mtb) is the primary causative 
agent of TB and strains of Mtb that are resistant to the antibiotics currently used to treat TB are 
rapidly emerging worldwide.  
The tuberculin skin test (TST) has traditionally been used to diagnose TB infection for almost a 
century. However, TST results are often confounded by non-tuberculous mycobacterium 
infection (NTMs), BCG, individual immune status, the method of test administration and the 
reading of results. The fairly recent identification of early secreted antigenic target 6 (ESAT-6) 
and the related culture filtrate protein (CFP-10), that are not present in BCG or most non-
tuberculous mycobacteria, has been of major significance in the development of TB diagnostics. 
These proteins are coded within the region of difference 1 (RD-1) of the Mtb genome. In persons 
with latent TB infection (LTBI), memory T cells produce interferon-gamma (IFN-γ) in response 
to Mtb antigens. There are two commercially available Interferon-Gamma Release Assays 
(IGRAs) that are licensed for use in many countries: QuantiFERON TB Gold (Cellestis®) and T-
Spot (Oxford Immunotec®).  
IGRAs such as QuantiFERON (QFT) have been recommended for serial testing but data is very 
limited on the interpretation of repeat IGRA testing. Although existing studies are limited, they 
suggest that conversions, reversions and non-specific variations do occur with IGRAs as they do 
with TST, and to date there is no consensus on how to define and/or interpret these conversions 
and reversions. A known increased risk of developing active TB disease is associated with TST 















1. To determine the risk of developing active TB disease in adolescents with a converted 
QuantiFERON status compared to a group whose QuantiFERON status remained 
negative throughout the study. 
2. To determine relative risk using different definitions of conversion. 
Study Design: This study is an extension of a prospective epidemiological study of TB disease 
and infection in adolescents in the Worcester and surrounding areas in the Western Cape 
carried out from 2005 to 2009, in which 6363 participants were enrolled from local public 
schools. In this follow-on study, a subset of adolescents who were identified to have converted 
their QFT status during the original study will be followed up and observed for the occurrence 
of active TB disease over a period of two years. A similar sized, random sample of participants 
identified to have a QFT status that remained negative throughout the original study will be 
used as the control group. 
Evaluations and Follow-up: Participants that are successfully enrolled into this study will be 
screened for TB disease at baseline and every 6 months thereafter based on set criteria. A total of 
5 study visits per participant (including baseline evaluation) will be carried out over the 2 years 
of follow-up. All participants suspected of having TB disease or otherwise identified to have TB 
disease will have all study tests carried out and referred for treatment if necessary. In addition, 
all participants will also be monitored for the development of active TB disease through the 
















With tuberculosis (TB) accounting for nine million new cases of TB and 1.8 million deaths 
reported in 20071, it is amongst the world’s most lethal infectious agents causing more adult 
deaths than any other pathogen. TB has been declared a global health emergency by the World 
Health Organisation (WHO). Mycobacterium tuberculosis (Mtb) is the primary causative agent of 
TB and strains of Mtb that are resistant to the antibiotics currently used to treat TB are rapidly 
emerging worldwide. In developing countries where TB is endemic, extensive neonatal 
vaccination programs using attenuated strains of Mycobacterium bovis, collectively referred to as 
Bacillus Calmette-Guerin (BCG), have reportedly reduced the incidence of severe forms of 
childhood TB. To date, no vaccine has been shown to reliably prevent pulmonary tuberculosis 
in adults. Various studies show the protective efficacy of vaccination with BCG against the 
development of TB in adults has ranged from 80% in some studies to little or no efficacy in 
other studies where the TB burden is greatest.2 
A key method of helping to reduce the global TB burden particularly in developing countries is 
the identification and treatment of latent tuberculosis infection (LTBI), traditionally diagnosed 
using the tuberculin skin test (TST) which is dependent on a delayed hypersensitivity response 
to purified protein derivative (PPD) of Mtb. TST is a relatively cheap test which requires no 
laboratory component and has been used as the standard test in the identification of Mtb 
infection for almost a century. It is important to note that TST results can however be 
confounded by non-tuberculous mycobacterium infection (NTMs), BCG, individual immune 
status, the method of test administration and the reading of results. In addition two patient 
visits are required, one for administration and one for reading, 48-96 hours apart. The fairly 
recent identification of early secreted antigenic target 6 (ESAT-6) and the related culture filtrate 
protein (CFP-10), that are not present in BCG or most non-tuberculous mycobacteria, has been 
of major significance in the development of TB diagnostics. These proteins are coded within the 
region of difference 1 (RD-1) of the Mtb genome. In persons with LTBI, memory T cells produce 












There are two commercially available Interferon-Gamma Release Assays (IGRAs) that are 
licensed for use in many countries: QuantiFERON TB Gold (Cellestis®) and T-Spot (Oxford 
Immunotec®). Operationally, the advantages of IGRAs over TST are that these assays require 
one visit with results available in 24 hours; they are able to avoid boosting due to repeat testing 
and have a standardized interpretation.4 IGRAs have their limitations in that they require an 
equipped laboratory with trained personnel and like TST, they cannot distinguish between 
latent and active TB disease.  
One such IGRA will be used as the basis of comparison in this study, the QuantiFERON Gold 
In-Tube (QFT-G IT) assay which was recently approved by the US Food and Drug 
administration (FDA). This is a modified version of the QuantiFERON Gold (QFT-G) assay.  
When compared to QFT-G, the newer version QFT-G IT includes a third antigen called TB7.7 
and requires only 3ml of blood compared to the 16ml required by QFT-G. This additional 
antigen is thought to enhance the sensitivity of the assay without reducing its specificity. Both 
versions of QuantiFERON (QFT) are based on the 16-24h whole blood enzyme-linked 
immunorsorebnt assay (ELISA).5  
IGRAs such as QFT have been recommended for serial testing but data is very limited on the 
interpretation of repeat IGRA testing. Although existing studies are limited, they suggest that 
conversions, reversions and non-specific variations do occur with IGRAs as they do with TST, 
and to date there is no consensus on how to define and/or interpret these conversions and 
reversions.6 If a simple negative to positive definition is used, then conversion rates may be 
higher with IGRAs than with TST. These higher conversion rates could indicate that these 
assays are more sensitive at identifying new infections but this has not been established.7 
It has been shown that the risk of TB disease after a peak in early childhood begins to increase 
from about 12 years of age and has a second peak in early adulthood. For this reason the 
adolescent age group is often considered a priority group for vaccination against TB.8 This is 
supported by data on the age distrubution of TB cases from the Cape Town Metropole in 2002 












this pattern has been observed in many countries spanning a variety of geographic, cultural and 
economic settings where the annual risk of infection is high9. Studying the prevalence of 
infection, the annual risk of TB infection and the risk of TB disease given infection in 
adolescents, in areas where vaccine trials are under way is of high priority. 



















Reference:  Provincial Authority Western Cape Province, Unpublished Data 2004 
As an extension of a prospective epidemiological study of TB disease and infection in 
adolescents in the Worcester and surrounding areas in the Western Cape carried out from 2005 
to 2009, a subset of adolescents who were identified to have converted their QFT status will be 
followed up and observed for the occurrence of active TB disease over a period of two years. A 
known risk of developing active TB disease is associated with TST conversions. This risk in 
















3. RESEARCH AIM AND OBJECTIVES 
3.1. Research Question 
Can QuantiFERON conversion be used as a predictor in the development of active TB disease in 
adolescents? 
3.2. Hypothesis 
QuantiFERON conversion in adolescents represents a higher risk of progression to TB disease 
when compared to adolescents who do not undergo QuantiFERON conversion. 
3.3. Objectives 
1. To determine the risk* of developing active TB disease in adolescents with a converted 
QuantiFERON status compared to a group whose QuantiFERON status remained 
negative. 
2. To determine relative risk using different definitions of conversion. 
*The risk as measured by the incidence rate of TB disease. This is the most likely end point to be used in a 
Phase III clinical trial of a new TB vaccine in adolescents.  
Case definition - A case of tuberculosis will be defined as any case that is diagnosed by a 
physician and confirmed by two or more smear positive for AFB and/or one positive culture 
for Mycobacterium tuberculosis. 
Other case definitions (e.g., abnormalities on a chest radiograph, symptomatic response 
therapy, etc) may be used as alternate definitions which may increase sensitivity but may 
increase the number of false positives. 
QuantiFERON conversion definition - A change in QFT status from negative at baseline 













4. STUDY METHODS 
4.1. Study Design 
This is an extension of a prospective, observational cohort study conducted in adolescents 12-18 
years old (at time of enrolment into original study) in Worcester and its surrounding areas, with 
no experimental interventions. Participants whose QFT-G IT test status converted from having 
been negative at baseline during the original cohort study to being positive at a subsequent 
timepoint will be followed up for at least a further two years after their 2-year study visit or for 
a maximum of 5 years post conversion and observed for the development of active TB disease. 
A similar sized, randomly sampled control group of participants who have remained QFT-G IT 
negative throughout the original cohort study will undergo similar follow-up. As with the 
original cohort study, hospital admission and mortality surveillance will be conducted for all 
participants.  
4.2. Study Procedures 
Inclusion and Exclusion Criteria 
Inclusion Criteria 
 Male and female adolescent volunteers who were  enrolled into the original cohort 
study, living in the greater Worcester area and attending public schools 
 
 Participants identified to have converted their QFT-G IT test status from negative at 
baseline to positive at a subsequent timepoint in the original cohort study 
OR  
Participants who were randomly selected from those whose QFT-G IT status remained 
negative throughout the original cohort study 
 
 Informed consent from participants and/or participant’s parent/legal guardian and 
informed assent from adoelscents still <18 years of age 
 
Exclusion Criteria 














Subject Selection and Screening 
It is estimated that approximately 600 out of the 800 participants who have been identified to 
have converted their QFT-G IT status will agree or be available to participate in this study. A 
similar sized random sample of participants identified from the existing database, whose QFT-
G IT status remained negative throughout will be selected as a control group. Study purpose 
and procedures will be explained to participants and parents. Consent for this additional 
follow-up will be obtained using supplementary consent/assent forms to the existing 
consent/assent forms used for the original cohort study. Participants who are 18 years or older 
at the time they are approached will be asked to sign consent for this extended follow-up. 
Participants who are younger than 18 years of age will require parental consent and participant 
assent for the extended follow-up period. 
Study Visits 
Baseline Evaluation 
Once consent and/or assent forms have been signed, participants will be considered enrolled, 
assigned a subject identification number and baseline (Study Day 0) evaluations must be 
completed as layed out in the data-capture form (DCF) (Appendix C). Participants will be asked 
questions pertaining to their medical history. This assessment will include details of current or 
past TB disease, history of close contact with an individual with confirmed TB disease, current 
symptoms of TB disease, and history of hospitalisations since last study visit as well as the 
diagnosis of acute or chronic diseases. Demographic characteristics (participant’s gender, DOB, 
race/ethnicity, occupation and monthly income if out of school and employed) will be reviewed 
with the participant. If the participant has had a new household/close TB contact since the last 
study interview or the participant is symptomatic of TB disease or currently on TB treatment, 
they will be referred for TB investigation where all study tests must be completed described 













Subsequent 6-Monthly Study Visits 
Participants will have follow-up visits every 6 months following their baseline evaluation (6, 12, 
18, 24 months) where they will be repeatedly assessed for current or past TB disease, history of 
close contact with an individual with confirmed TB disease, current symptoms of TB disease, 
and history of hospitalisations as well as the diagnosis of acute or chronic diseases since last 
study visit. If necessary participants will be referred for TB investigation where all study tests as 
described below must be completed. 
Two year Visit 
This will be the final study visit and participants will be assessed as before. Study staff  are to 
complete a checklist pertaining to participant’s status at the end of the study (study completed, 
loss to follow-up (LTFU), withdrew, death).  
In-Between Visits 
All participants will be subject to passive surveillance for tuberculosis through ongoing 
checking of TB registers at local clinics and hospitals until all 2 year study visits have been 
completed. Tuberculosis cases picked up this way (or by parent/participant contacting study 
staff) will be referred for TB investigation and all study tests are to be completed. These will be 
captured as ‘In-between Visits’ on the data-capture form. 
Specimen Collection 
Study staff will follow SATVI standard operating procedures used in the original cohort study 
regarding sputum specimen collection, processing, storage and shipment. 
TB Evaluation and Diagnostic Processes 
Once referred for TB investigation, following an assessment of participant clinical history and 












sputum samples. If a participant fails to produce sputum, they will be referred for induced 
sputum procedures. TB culture will be performed on all sputum samples.  A chest x-ray will be 
performed as well as an HIV test when permitted by the participant. Tests will only be carried 
out if outstanding from participant’s medical records. 
All participants will individually receive counseling in a confidential setting on the results of 
their tests and given a written summary of the test results. 
All test results will be communicated to the study participant’s medical care provider who will 
make all decisions related to treatment and will manage any treatment that is needed. If the 
sputum specimen is smear or culture positive the results will also be reported to the public 
sector tuberculosis control program. TB treatment is available at no cost to the public at all TB 
control programme clinics. 
Medical care providers, especially clinicians in the public sector TB clinics, will be informed 
about the extension of the study and asked to continue referring all individuals enrolled in the 
study for the diagnostic process (only outstanding tests from medical records will be carried 
out).  
Study staff will arrange to record whether treatment is started, any treatment prescribed, the 
date started, the date stopped and the treatment outcome. Outcome will be recorded using 
WHO DOTS program definitions for cured, completed, failed, interrupted, transferred and 
died. 
Participant Withdrawal 
As participation in this study is voluntary, all study participants will reserve the right to 
withdraw from the study for whatever reasons they see fit. It will be made clear that they can 
do so without facing any penalty or loss of benefits to which they are otherwise entiled to. All 













5. COMPENSATION AND PARTICIPANT INCENTIVES 
Particpants will receive no monetary compensation*. They will be given a packet of crisps and a 
coke at each study visit. 
*In the original cohort study, participating schools were offered incentives (e.g., book vouchers or IT 
equipment) proportional to the number of learners per school, or cash for another purpose. An equal rate 
per learner was also paid to a maximum of $2,000 per school. An amount of R50 (at every occasion of 
blood draw) in the form of a non-cash payment such as a voucher was paid to learners who agreed to 
participate in the study in lieu of the time offered and the discomfort experienced. 
6.  MORBIDITY AND MORTALITY SURVEILLANCE 
Due to the fact that no experimental product is being administered in this study, there will be 
no formal adverse event surveillance. Identification of acute illness and/or injuries for all 
participants will be through passive surveillance of hospital records and documentation of all 
hospital visits by participants. This information will be recorded on the DCF.  
An autopsy will be requested for participants who die during the study. Due sensitivity will be 
exercised in approaching respective families to whom it will be made clear that there will be no 
loss of benefits or any other negative consequences should they refuse for the autopsy to be 
carried out. Regarding autopsy results, counseling will be provided to families where necessary. 
Autopsies will be carried out by a district surgeon in Worcester working in consultation with a 
pathologist at the University of Cape Town. 
When deaths are due to unnatural causes such as violence or motor vehicle accidents, autopsies 
are required by law and these will be conducted by the district surgeon. 
Parents/guradians will be given the option of a verbal autopsy should they refuse for a full or 
targeted autopsy to be carried out. 
Premature Study Termination 












 If the ethics review board instructs premature termination 
 If the sponsor decides to discontinue the study for financial or other reasons 
 If in the best interest of the participants, continuation of the study is thought to be 
harmful 
 
7. STATISTICAL CONSIDERATIONS 
Sample Size Calculation and Estimates of TB Disease Incidence 
The primary endpoint will be calculated as the cummulative incidence of new TB disease cases 
in participants who have converted their QFT status, relative to the cummulative incidence of 
new TB disease cases in participants in the randomly sampled control group of participants 
whose QFT status was shown to have remained negative throughout the study. 
A new case of TB will be defined as any participant diagnosed with TB by a physician and 
confrimed by two smears positive for acid fast bacilli (AFB) and/or one positive culture. 
It is estimated that of the 800 participants identified to have converted their QFT status, 
approximately 600 will agree to be part of this extended follow-up study. A similar sized 
randomly sampled control group will be selected from participants who were identified to have 
remained QFT negative throughout the study. 
The predicted cumulative incidence rate of TB over the two years following QFT conversion is 
3% based on preliminary results obtained from the original cohort study. The expected sample 
size of 600 will give a rate estimate [95% confidence interval (CI)] of 3% (1.6% to 4.4%) in the 
post-conversion group. The predicted cumulative incidence rate of TB over two years in the 
QFT negative group (control group) is 0.8% based on preliminary results from the original 
cohort study.  Given a sample size of 600, the expected rate estimate [95% CI] is 0.8% (0.09% to 














Statistical Summaries/Analyses and Computer Methods 
A study report will be generated at the end of the study follow up, once all data queries have 
been identified and cleared. Following the locking of the databese, data will be imported from 
the database for statistical analysis in STATA 10 software under a Windows Operating System. 
All results will be reported as appropriate effects with a measure of precision [95% CI]. 
8. DATA MANAGEMENT 
All information will be recorded on a data capture form (DCF). Where necessary, a specific 
addendum will be completed and attached to the DCF in cases such as withdrawal and/or 
hospitalisation. Data collected on DCF’s will be entered into a relational Microsoft Access 
database. Data will be entered continuously as the study progresses. A Data Manager will be 
responsible for creating the database, as well as monitoring all entries. Only authorised personel 
will be granted authorisation to access the database. 
DCF’s will be periodically checked by the study investigator (or designee) to ensure all 
information is captured correctly and that any corrections made on the DCF adhere to the 
requirements of the Good Clinical Practice (GCP) guidelines. Data will be stored safely to 
ensure confidentiality of particpants is maintained. On completion of the study, the database 
will be checked, data cleaned and all outstanding queries will be resolved. The database will 
then be locked and no further changes can be made. 
All study records (source documents, signed informed consent forms, copies of DCF’s, IRB/IEC 
correspondence and approval letters etc) will be kept safely for a period of time of up to 2 years 
following the completeion of the study. On request, the Sponsor may inspect all study records 
and these should be made available. 
The reliability of information collected for this study will be optimised by ensuring these 
measures are in place: 













 Use of a clear and simple DCF 
 Periodic checks of database by Data Manager and Study Manager 
 Ensuring all participants enrolled into the study meet inclusion criteria 
 
9. ETHICS AND COMMUNICATION 
Ethics and Regulatory Considerations 
All study procedures are in accordance with the Declaration of Helsinki. The study protocol 
and informed consent form will be reviewed and approved by the Institutional Review Board 
(IRB) or Independent Ethics Committee (IEC) of the Aeras Global TB Vaccine Foundation and 
the University of Cape Town prior to any protocol-specified procedures being conducted. 
Reports are to be made to the IRB as to the progression of the study at least once a year. 
Written informed consent will be obtained from study participants over 18 years and parents/ 
legal representative of participants younger than 18 years prior to enrolment and the 
conducting of any protocol-specified procedures. 
Each participant will be assigned a coded number and together with the parcipant’s initials, will 
form the participant identification (ID) number which will be used to identify the participant on 
laboratory specimens, source documents, DCF, study reports etc. Participants will retain ID 
numbers previously assigned to them in the main study. This will ensure confidentiality is 
maintained. Written permission will be obtained from the participant/legal representative 
before any participant information is released except as required by monitoring and/or auditing 
of the study by the Sponsor or local regulatory authorities. 
Institutional Review Board or Independent Ethics Committee 
Prior to the start of the study, the investigator must obtain written approval for the study 
protocol and informed consent form from the IRB or IEC. All study documents requiring 
approval from the IRB/IEC must be submitted for approval. Modifications/ammendments to the 












necessary to eliminate immediate harm to the particiant or when modifications only involve 
logistical/administrative aspects of the study. 
An established community advisory board is available for consultation should the need arise.  
Informed Consent 
Informed consent will be documented by using a written document approved by the IRB/IEC 
(APPENDIX B). Informed consent must be obtained from all participants and/or the 
participant’s legal representative who after a clear explanation by the investigator (or qualified 
designee) in their home language as to the purpose of the study, its goals, expected benefits and 
known/potential risks will sign on the designated page of the document.  
All information must be provided in a way that is clear and understandable for the participant 
and participant’s legal representative. The document will have translations in Afrikaans and 
isiXhosa to facilitate for better understanding. The participant/ participant’s legal representative 
should be given information as to who to contact in the event of a study-related illness. It will 
be made clear to the participant/ participant’s legal representative that no experimental 
intervention will be implemented in this study and no blood draws or TST’s will be carried out. 
It will also be made clear to the partic pant/participant’s legal representative that participation 
in this study is voluntary and that they are free to withdraw from the study at anytime for 
whatever reason they see fit without any penalty or loss of benefits to which they are otherwise 
entitled. 
Relationship with Regional Health Services in the Study Area 
The regional and local TB control program staffs are aware of the study and will be notified of 
its extension and requested to continue assisting and supporting the study. All participants will 
be informed of their results by the study team. The policy for the South African TB control 
program is that they do not offer treatment to person’s with LTBI over the age of 5 years. 
Persons with microbiological or other evidence of TB disease will be prescribed a standard 












Results of all TB investigations will be communicated to the participant and participant’s 
medical care provider. If the sputum smear or culture are positive, and the participant does not 
have a medical care provider they will be given a referral letter to their nearest public sector TB 
treatment clinic. Free TB treatment is available to this community. Results of positive smears 
and cultures will also be reported to the tuberculosis control program. 
Participants will be given a TB Fact sheet that describes TB signs and symptoms as well as the 
relationship between TB and HIV (APPENDIX F).  Participants will be advised to visit their 
nearest clinic should any of them arise. 
10. REPORTING AND PUBLICATION 
The findings of the study will be reported back to the sponsor and relevant persons within the 
community. All manuscripts, abstracts and presentations using data from this study must be 
reported to the sponsor 30 days prior to their submission. A manuscript(s) will be published in 























This protocol was adapted from an original cohort study protocol - A Prospective 
Epidemiological Study of TB Disease and TB Infection in Adolescents in the Worcester and 
Surrounding Areas, Western Cape Province, South Africa [Protocol Number EPI-002-ZA], 2005-
2009. Prof. Gregory Hussey (Principal Investigator) and Dr Hassan Mahomed (Study Manager) 
were responsible for both the protocol development and study procedures of the original cohort 
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APPENDIX A: Timeline 
 Year 1(months) Year 2(months)  Year 3(months) 
1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 
Protocol  
Development 
                                 












    1st year follow-up 2nd  year follow-up      
Data Cleaning        Continuous data-cleaning    
Data Analysis & 
Study Report 
Preparation 
                 Preliminary analysis begins after 1 year follow-up  
Final Study 
Report  
                                  












APPENDIX B: Participant Consent Form 
Supplementary Participant Information and Consent Form for the extension of the 
Adolescent Cohort Study 
 
UNIVERSITY OF CAPE TOWN / AERAS GLOBAL TB VACCINE FOUNDATION 
Participant Information and Consent Form 
 
Protocol Title: A prospective Epidemiological Study of TB Disease and TB infection in 
Adolescents in the Worcester and Surrounding Areas, Western Cape Province, South 
Africa 
You have agreed before to take part in a study of TB in adolescents. To remind you:  
This research study was done by the South African TB Vaccine Initiative (SATVI), Institute 
of Infectious Disease and Molecular Medicine, University of Cape Town Medical School, 
Anzio Rd, Observatory, Cape Town in collaboration with the Aeras Global TB Vaccine 
Foundation, USA. The person in charge of the study is Professor Gregory Hussey, Director 
of SATVI. Your child has completed follow up for that study. We would like to continue 
follow up for a further two years in some of the children who took part in that study. The 
children we will follow up are either those who became infected with TB during the study 
period or those children who showed no sign of becoming infected during the study period.  
This was shown by blood tests done during the study. 
Voluntary Participation 
You may choose not to continue in the study. As a result of that decision, no health care will 
be taken away from you if you say no. You will not pay a penalty or lose any benefits you 
have earned if you say no. You are free to leave the study at any time. 
Reason for further follow up  
We want to study a new blood test for diagnosing TB infection and TB disease. We want to 
know if the new blood test shows us those who will develop TB.  
When somebody is not infected with TB, the new test gives a negative result. This 
uninfected individual may then become infected and when tested again, the test will give a 
positive result. This change with respect to the test results from negative to positive is called 
conversion. We want to see how many of the children who converted in the study develop 
TB disease. We want to compare the number of children with TB disease in those who have 














Procedures to be followed  
If you agree to continue participating in the study we will ask you some questions about 
your health status since you were last seen by study staff.  
Sputum Testing: If you have new TB-related symptoms or have lived with someone who 
has been diagnosed with TB disease since the last visit by a study team member, you will be 
asked to provide two sputum samples. You may be asked to produce a sputum sample 
immediately or will be given containers to take home and asked to produce sputum 
specimens early in the morning. A nurse will explain what sputum is and how to produce it. 
If you are still not able to produce sputum, a nurse will assess him/her. If needed, we will 
arrange for him/her to have more sputum tests, induced sputum, a chest x-ray and an 
assessment by a doctor. The induced sputum procedure will be explained in another 
consent form.  
Follow-up: 
Individual Follow-up 
A study team member will visit you every six months. At this visit the study team member 
will interview you about TB signs and symptoms and TB in the household.  
If you have new symptoms and have been in contact with a new TB case, you will be asked 
to produce sputum for tests to see if they have TB disease.  
Hospital and Clinic Follow-up 
Study staff will be reviewing records of local area hospitals and clinics. When they find 
records of children participating in the study they will record information about the visit. 
They will record the diagnosis at discharge. This information will help to identify those who 
have been TB diagnosed in hospitals or clinics. When you sign this form, you will be giving 
us permission to get these records. 
Study Close Out: The study will last for up to two years from the start date. At the last visit 
you will be asked about TB signs and symptoms. We will also ask about TB cases who 
might live in the home. If you are suspected of TB disease, you will be asked to produce 
sputum for tests to see if you have TB disease. You may be asked to have a chest x-ray if the 
study staff feel that this is necessary. 
Cause of Death Investigations: It is important to know the cause of death if someone passes 
away. It is very rare for a child in this age group to pass away. However, if this should 












death. This will require further investigations. We will approach your parents or legal 
guardian to discuss these with them in more detail should you pass away.  
Study Eligibility  
You cannot participate in this further follow up part of the study if you plan to move from 
the study area or out of Cape Town in the next two years. There may be other reasons that 
the study doctor or his staff will talk to you about. 
Risks and Benefits to You 
You will have the benefit of early referral for treatment should TB or any other disease be 
detected. The screening procedures used will not always detect early cases of TB so if you 
develop symptoms of TB you should still seek advice from your normal doctor or clinic 
about this. You will be provided with a list of these symptoms. 
Compensation 
No compensation will be paid to you for taking part in this further follow up phase. 
Privacy 
You will receive a copy of this consent form. We will keep your study records private to the 
best of our ability. Nobody but the researchers in this study will see your records unless you 
say OK. Your name will not be in any publication written from this study. 
Contact Information for Questions or Concerns 
This study has been approved by the Research Ethics Committee, Faculty of Health 
Sciences, University of Cape Town, and the Research in Human Subjects/Institutional 
Review Board of the Aeras Foundation, which approves all trials involving human subjects. 
The study has also been seen and approved by the Regional Director of the Department of 
Health in the Boland Overberg Region. 
If you have any concerns about your rights as a research participant you should contact the 
secretary of the research committee at the Faculty of Health Sciences on (021) 406 6492. 
If at anytime you have questions or concerns about this study or are injured as a result of 
participation in this study you should contact: 
Principal Investigator: 
Professor Gregory Hussey, South African TB Vaccine Initiative, Institute of Infectious 












Observatory, Cape Town, South Africa. Telephone (27) 21 406 6013/14 Fax (27) 21 406 6081 
email: gregory.hussey@uct.ac.za 
Program Manager: 
Elmarie Simon. SATVI Project Office, Brewelskloof Hospital, Worcester, Western Cape 







































Consent/Assent To Take Part In This Study 
I have read and discussed this concent form and understand the contents.  My questions 
have been answered.  I freely agree to take part in the study and agree to have my blood 
stored for use in future research of the TB germ and germs related to the TB germ. 
      
 
      __________________________________________________________________________________ 
      Name of study participant/ child (please print) 
                
              Study participant under 21 years of age (tick only if applicable and complete below) 
  
             _______________________________________________________________________________ 
             Signature of participant      Date 
 
            ____________________________________________________________________  
            Name of study personnel taking assent (please print) 
 
             ____________________________________________________________________ 
             Signature of study personnel taking assent   Date 
 
              Interpreter used (tick only if applicable) 
 
  Witness used (tick only if applicable; tick one below to describe witness) 
      
         Study personnel  Independent/impartial person 
  
 
              ____________________________________________________________________ 
 Name of witness (please print) 
 
              ____________________________________________________________________ 
             Signature of witness 
 




















APPENDIX C: Parental Consent Form 
Supplementary Parent/ Guardian Information and Consent Forms for the extension of the 
Adolescent Cohort Study 
UNIVERSITY OF CAPE TOWN / AERAS GLOBAL TB VACCINE FOUNDATION 
Parent/Guardian Information and Consent Form 
 
Protocol Title: A prospective Epidemiological Study of TB Disease and TB infection in 
Adolescents in the Worcester and Surrounding Areas, Western Cape Province, South 
Africa 
You have agreed before for your child to take part in a study of TB in adolescents. To 
remind you:  
This research study was done by the South African TB Vaccine Initiative (SATVI), Institute 
of Infectious Disease and Molecular Medicine, University of Cape Town Medical School, 
Anzio Rd, Observatory, Cape Town in collaboration with the Aeras Global TB Vaccine 
Foundation, USA. The person in charge of the study is Professor Gregory Hussey, Director 
of SATVI. Your child has completed follow up for that study. We would like to continue 
follow up for a further two years in some of the children who took part in that study. The 
children we will follow up are either those who became infected with TB during the study 
period or those children who showed no sign of becoming infected during the study period.  
This was shown by blood tests done during the study. 
Voluntary Participation 
You may choose for your child not to continue in the study. As a result of that decision, no 
health care will be taken away from you or your child if you say no. Neither you nor your 
child will pay a penalty or lose any benefits you have earned if you say no. Your child is free 
to leave the study at any time. 
Reason for further follow up  
We want to study a new blood test for diagnosing TB infection and TB disease. We want to 
know if the new blood test shows us those who will develop TB.  
When somebody is not infected with TB, the new test gives a negative result. This 
uninfected individual may then become infected and when tested again, the test will give a 
positive result. This change with respect to the test results from negative to positive is called 
conversion. We want to see how many of the children who converted in the study develop 
TB disease. We want to compare the number of children with TB disease in those who have 













Procedures to be followed  
If you agree for your child to continue participating in the study we will ask you some 
questions about your child’s healthstatus since your child was last seen by study staff. We 
will then ask your child to agree to continue being in the study. If he or she agrees, we will 
then ask your child the same questions to confirm what you have told us.  
Sputum Testing: Children who have new TB-related symptoms or have lived with someone 
who has been diagnosed with TB disease since the last visit by a study team member will be 
asked to provide two sputum samples. Your child may be asked to produce a sputum 
sample immediately or he/she will be given containers to take home and asked to produce 
sputum specimens early in the morning. A nurse will explain what sputum is and how to 
produce it. If your child is still not able to produce sputum, a nurse will assess him/her. If 
needed, we will arrange for him/her to have more sputum tests, induced sputum, a chest x-
ray and an assessment by a doctor. The induced sputum procedure will be explained in 
another consent form.  
Follow-up: 
Individual Follow-up 
A study team member will visit your child every six months. At this visit the study team 
member will interview your child about TB signs and symptoms and TB in the household.  
If your child has new symptoms and has been in contact with a new TB case, your child will 
be asked to produce sputum for tests to see if they have TB disease.  
Hospital and Clinic Follow-up 
Study staff will be reviewing records of local area hospitals and clinics. When they find 
records of children participating in the study they will record information about the visit. 
They will record the diagnosis at discharge. This information will help to identify those who 
have been TB diagnosed in hospitals or clinics. When you sign this form, you will be giving 
us permission to get these records. 
Study Close Out: The study will last for up to two years from the start date. At the last visit 
your child will be asked about TB signs and symptoms. We will also ask about TB cases who 
might live in the home. If your child is suspected of TB disease, they will be asked to 
produce sputum for tests to see if they have TB disease. Your child may be asked to have a 












Cause of Death Investigations: It is important to know the cause of death if someone passes 
away. It is very rare for a child in this age group to pass away. However, if this should 
happen, we would want to know if TB or a related condition has something to do with the 
death. This will require further investigations. We will approach you to discuss these with 
you in more detail should your child pass away.  
Study Eligibility  
Your child cannot participate in this further follow up part of the study if you plan to move 
from the study area or out of Cape Town in the next two years. There may be other reasons 
that the study doctor or his staff will talk to you about. 
Risks and Benefits to You 
Your child will have the benefit of early referral for treatment should TB or any other 
disease be detected. The screening procedures used will not always detect early cases of TB 
so if your child develops symptoms of TB you should still seek advice from your normal 
doctor or clinic about this. Your child will be provided with a list of these symptoms. 
Compensation 
No compensation will be paid to you or your child for taking part in this further follow up 
phase. 
Privacy 
You will receive a copy of this consent form. We will keep your child’s study records private 
to the best of our ability. Nobody but the researchers in this study will see your records 
unless you say OK. Your name will not be in any publication written from this study. 
Contact Information fro Questions or Concerns 
This study has been approved by the Research Ethics Committee, Faculty of Health 
Sciences, University of Cape Town, and the Research in Human Subjects/Institutional 
Review Board of the Aeras Foundation, which approves all trials involving human subjects. 
The study has also been seen and approved by the Regional Director of the Department of 
Health in the Boland Overberg Region. 
If you have any concerns about your rights as a research participant you should contact the 
secretary of the research committee at the Faculty of Health Sciences on (021) 406 6492. 
If at anytime you have questions or concerns about this study or are injured as a result of 














Professor Gregory Hussey, South African TB Vaccine Initiative, Institute of Infectious 
Disease and Molecular Medicine, University of Cape Town Medical School, Anzio Road, 
Observatory, Cape Town, South Africa. Telephone (27) 21 406 6013/14 Fax (27) 21 406 6081 
email: gregory.hussey@uct.ac.za 
Program Manager: 
Elmarie Simon. SATVI Project Office, Brewelskloof Hospital, Worcester, Western Cape 































Consent to Take Part in this Study 
I have read and discussed this consent form and understand the contents.  My questions 
have been answered.  I voluntarily consent to have my child participate and agree to have 
my child’s blood stored for use in future research of the TB germ and germs related to the 
TB germ. 
      
 
             ____________________________________________________________________________ 
             Name of study participant/ child (please print) 
                
              Study participant under 21 years of age (tick only if applicable and complete below) 
 
  
             ___________________________________________________________________________ 
             Signature of participant      Date 
 
         _________________________________________________________________ 
           Name of parent / legal guardian (please print) 
 
           _________________________________________________________________ 
           Signature of parent/ legal guardian    Date 
 
 
            _________________________________________________________________ 
            Name of study personnel taking assent (please print) 
 
 
             _________________________________________________________________ 
             Signature of study personnel taking assent   Date 
 
              Interpreter used (tick only if applicable) 
 
  Witness used (tick only if applicable; tick one below to describe witness) 
      
         Study personnel  Independent/impartial person 
  
 
              ____________________________________________________________________ 
 Name of witness (please print) 
 
 
              ____________________________________________________________________ 
             Signature of witness 
 






















A Prospective Epidemiological Study of TB Disease and TB Infection in 
Adolescents in the Worcester and Surrounding Areas, Western Cape 
Province, South Africa. 
Protocol Number: EPI-002-ZA 


























Participant Enrolment and Demographics (Study Day 0) 
Date of respondent interview ____/_______/200__ (DD/MON/YYYY) 
Respondent (please circle all that apply) Mother/ father/ guardian/ participant/ other 
Date of participant enrolment interview ____/_______/200__ (DD/MON/YYYY) 
 
Study group assigned (please circle) QFT Converter QFT non-Converter 
Information obtained from parent and confirmed with participant if less than 18years. Participant 
and/or respondent should have completed Informed Consent. 
 
Participant details and Socio-economic Information 
Participant’s Name/ Surname  
Participant DOB (DD/MM/YYYY)  
School (if still at school)  
Class (if still at school)  
Occupation/ grant (if NOT at school)  
Participant 18 years and older Gross 
monthly income (circle 1) 
 
None 1 - R1000 R1001 - 
R4000 
>R4000 Other      
 
Contact Information 
CONFIDENTIAL – for contact purposes only 
(Do not include in analysis database) 
Address (participant)  
Address  
Suburb/ Town  Postal code 
Home telephone #  
Work telephone (participant)  
Work telephone # (mother)  
Mother’s Cell #  












Father’s Cell #  
Work telephone # (guardian)  
Guardian’s Cell #  
Participant’s Cell #  
Name of usual doctor and Ph No   
 
Study Day 0 
TB Contact History 
Has anyone with whom the participant is living with been 
diagnosed with TB since Study Day 720 of the previous study? 
(please circle one) 
Y N Unk 
If so, who? (specify relationship to participant: father, mother, 
sibling, grandparent, aunt, uncle, cousin, friend, lodger) 
 
If yes, since when? (month, year)   
At what clinic? (specify the name of the clinic, or indicate 
‘Ukn’ if not known) 
 
If the participant has a new household TB contact since the last study interview (Study Day720), refer for TB 
investigation. 
History of TB since Study Day 720 
Was participant investigated for TB since Study Day 
720 of the previous study? 
Y N 
If yes, when? (DD/MON/YYYY) ____/_______/200____ 
If yes, by who? (specify the name of the clinic, or 
indicate ‘Ukn’ if not known) 
 
Was the participant put on TB treatment since Study 
Day 720 of the previous study? 
Y N 
If yes, when? (DD/MON/YYYY) ____/_______/200____ 
If yes, at what clinic? (specify the name of the clinic, 
or indicate ‘Ukn’ if not known) 
 
If the participant is currently on TB treatment for TB or is under investigation for TB, the results of their 
investigations must be obtained. If any of the study procedures are not yet done, or if results are not available 
these procedures must be arranged (smears, cultures, chest x-ray and HIV test).  












Study Day 0 
Clinical History since Study Day 720 
Symptoms Please circle one for each symptom Specify number of 
weeks 
Unexplained cough Y N  
Unexplained fever Y N  
Haemoptysis Y N  
Unexplained weight loss Y N  
Unexplained night sweats Y N  
Other (specify) Y N  
Other (specify) Y N  
If the participant has at least one symptom for two weeks or more or haemoptysis which is new or worsening 
since last contact, refer for TB investigation. 
 
Medical History / Hospitalisation since Study Day 720 
Has the participant had any significant illness or been 
hospitalized since Study Day 720 of the previous 
study? 
Y N 
If yes, when? (month, year)  
If the participant reports significant illness or was hospitalized since Study Day720 of the previous study, fill in 
separate Hospitalisation DCF. 
 
Confirmed information with participant Yes No 
 
Parent/ Guardian interviewer 
 
 

















Study Day 0 
Is TB investigation needed for: 
Recent household contact since Study 
Day 720 of the previous study? 
Yes No 
Symptoms? Yes No 
Being investigated for TB or on TB 
treatment 
Yes No 
If any of the above are answered “Yes”, then issue 2 sputum jars with instructions. 
Sputum jars issued Yes No 
















Clinical assessment if unable to produce 
sputum 
Not needed TB highly 
likely 
TB highly unlikely 
Referred for sputum induction Yes No 
Sputum induction performed Yes No 






















Follow Up: 180 Days 
Was participant seen for a follow-up interview/evaluation? Y N 
If no, reason participant not seen for follow-up visit. (specify 
reason for refusal: not contactable, out of study area, 
withdrew consent, died) 
 
Date of interview/evaluation (DD/MON/YYYY) ____/_______/200____ 
Name of interviewer  
 
Clinical History since Study Day 0 
Symptoms Please circle one for each 
symptom 
Specify number of 
weeks 
Unexplained cough Y N  
Unexplained fever Y N  
Haemoptysis Y N  
Unexplained weight loss Y N  
Unexplained night sweats Y N  
Other (specify) Y N  
Other (specify) Y N  
If the participant has at least one symptom for two weeks or more or haemoptysis which is new or worsening 
since last contact, refer for TB investigation. 
 
Medical History / Hospitalisation since Study Day 0 
Has the participant had any significant illness or been 
hospitalized since the last study visit? 
Y N 
If yes, when? (month, year)  
















Study Day 180 
TB Contact History 
Has anyone with whom the participant is living with been 
diagnosed with TB since the last study visit? (please circle one) 
Y N Unk 
If so, who? (specify relationship to participant: father, mother, 
sibling, grandparent, aunt, uncle, cousin, friend, lodger) 
 
If yes, since when? (month, year)   
At what clinic? (specify the name of the clinic, or indicate 
‘Ukn’ if not known) 
 
If the participant has a new household TB contact since the last interview, refer for TB investigation. 
 
History of TB since Study Day 0 
Was participant investigated for TB since the last 
study visit? 
Y N 
If yes, when? (DD/MON/YYYY) ____/_______/200____ 
If yes, by who? (specify the name of the clinic, or 
indicate ‘Ukn’ if not known) 
 
Was the participant put on TB treatment since the last 
study visit? 
Y N 
If yes, when? (DD/MON/YYYY) ____/_______/200____ 
If yes, at what clinic? (specify the name of the clinic, 
or indicate ‘Ukn’ if not known) 
 
If the participant is currently on TB treatment for TB or is under investigation for TB, the results of their 
investigations must be obtained. If any of the study procedures are not yet done, or if results are not available 
these procedures must be arranged (smears, cultures, chest x-ray and HIV test).  
Note: Two sputum samples for smear and culture must be taken for each TB investigation. 
 
Study Day 180 
Study Examinations and Tests 
Is TB investigation needed for: 
New household TB contact since last visit? Yes No 












Being investigated for TB or on TB 
treatment 
Yes No 
If any of the above are answered “Yes”, then issue 2 sputum jars with instructions. 
Sputum jars issued Yes No 
Date sputum jars issued (DD/MON/YYYY) 1.____/_______/____ 
2.____/_______/____ 












Clinical assessment if unable to produce 
sputum 
Not needed TB highly 
likely 
TB highly unlikely 
Referred for sputum induction Yes No 
Sputum induction performed Yes No 

























Follow Up: 360 Days (1 Year) 
Was participant seen for a follow-up interview/evaluation? Y N 
If no, reason participant not seen for follow-up visit. 
(specify reason for refusal: not contactable, out of study 
area, withdrew consent, died) 
 
Date of interview/ evaluation (DD/MON/YYYY) ____/_______/200____ 
Name of interviewer  
 
Clinical History since Study Day 180 
Symptoms Please circle one for 
each symptom 
Specify number of 
weeks 
Unexplained cough Y N  
Unexplained fever Y N  
Haemoptysis Y N  
Unexplained weight loss Y N  
Unexplained night sweats Y N  
Other (specify) Y N  
Other (specify) Y N  
If the participant has at least one symptom for two weeks or more or haemoptysis which is new or worsening 
since last contact, refer for TB investigation. 
 
Medical History / Hospitalisation since Study Day 180 
Has the participant had any significant illness or 
been hospitalized since the last study visit? 
Y N 
If yes, when? (month, year)  

















Study Day 360 
TB Contact History 
Has anyone with whom the participant is living with been 
diagnosed with TB since the last study visit? (please circle one) 
Y N Unk 
If so, who? (specify relationship to participant: father, 
mother, sibling, grandparent, aunt, uncle, cousin, friend, 
lodger) 
 
If yes, since when? (month, year)   
At what clinic? (specify the name of the clinic, or indicate 
‘Ukn’ if not known) 
 
If the participant has a new household TB contact since the last interview, refer for TB investigation. 
 
History of TB since Study Day180  
Was participant investigated for TB since last study 
visit? 
Y N 
If yes, when? (DD/MON/YYYY) ____/_______/200____ 
If yes, by who? (specify the name of the clinic, or 
indicate ‘Ukn’ if not known) 
 
Was the participant put on TB treatment since the 
last study visit? 
Y N 
If yes, when? (DD/MON/YYYY) ____/_______/200____ 
If yes, at what clinic? (specify the name of the clinic, 
or indicate ‘Ukn’ if not known) 
 
If the participant is currently on TB treatment for TB or is under investigation for TB, the results of their 
investigations must be obtained. If any of the study procedures are not yet done, or if results are not available 
these procedures must be arranged (smears, cultures, chest x-ray and HIV test).  

















Study Day 360 
Study Examination and Tests 
Is TB investigation needed for: 
New household TB contact since last visit? Yes No 
New or worsening symptoms since last 
visit? 
Yes No 
Being investigated for TB or on TB 
treatment 
Yes No 
If any of the above are answered “Yes”, then issue 2 sputum jars with instructions. 
Sputum jars issued Yes No 
Date sputum jars issued (DD/MON/YYYY) 1.____/_______/____ 
2.____/_______/____ 












Clinical assessment if unable to produce 
sputum 
Not needed TB highly 
likely 
TB highly unlikely 
Referred for sputum induction Yes No 
Sputum induction performed Yes No 



















Follow Up: 540 Days 
Was participant seen for a follow-up 
interview/evaluation? 
Y N 
If no, reason participant not seen for follow-up visit. 
(specify reason for refusal: not contactable, out of study 
area, withdrew consent, died) 
 
Date of interview/ evaluation (DD/MON/YYYY) ____/_______/200____ 
Name of interviewer  
 
Clinical History since Study Day 360 




Unexplained cough Y N  
Unexplained fever Y N  
Haemoptysis Y N  
Unexplained weight loss Y N  
Unexplained night sweats Y N  
Other (specify) Y N  
Other (specify) Y N  
If the participant has at least one symptom for two weeks or more or haemoptysis which is new or worsening 
since last contact, refer for TB investigation 
 
Medical History / Hospitalisation since Study Day 360 
Has the participant had any significant illness or 
been hospitalized since the last study visit? 
Y N 
If yes, when? (month, year)  

















Study Day 540 
TB Contact History 
Has anyone with whom the participant is living with been 
diagnosed with TB since the last study visit? (please circle 
one) 
Y N Unk 
If so, who? (specify relationship to participant: father, 
mother, sibling, grandparent, aunt, uncle, cousin, friend, 
lodger) 
 
If yes, since when? (month, year)   
At what clinic? (specify the name of the clinic, or indicate 
‘Ukn’ if not known) 
 
If the participant has a new household TB contact since the last interview, refer for TB investigation. 
 
History of TB since Study Day 360 
Was participant investigated for TB since last study 
visit? 
Y N 
If yes, when? (DD/MON/YYYY) ____/_______/200____ 
If yes, by who? (specify the name of the clinic, or 
indicate ‘Ukn’ if not known) 
 
Was the participant put on TB treatment since the 
last study visit? 
Y N 
If yes, when? (DD/MON/YYYY) ____/_______/200____ 
If yes, at what clinic? (specify the name of the clinic, 
or indicate ‘Ukn’ if not known) 
 
If the participant is currently on TB treatment for TB or is under investigation for TB, the results of their 
investigations must be obtained. If any of the study procedures are not yet done, or if results are not available 
these procedures must be arranged (smears, cultures, chest x-ray and HIV test).  
















Study Day 540 
Study Examination and Tests 
Is TB investigation needed for: 
New household TB contact since last 
visit? 
Yes No 
New or worsening symptoms since last 
visit? 
Yes No 
Being investigated for TB or on TB 
treatment 
Yes No 
If any of the above are answered “Yes”, then issue 2 sputum jars with instructions. 
Sputum jars issued Yes No 
















Clinical assessment if unable to produce 
sputum 
Not needed TB highly 
likely 
TB highly unlikely 
Referred for sputum induction Yes No 
Sputum induction performed Yes No 




















Follow Up: 720 Days (2 Year) 
Was participant seen for a follow-up 
interview/evaluation? 
Y N 
If no, reason participant not seen for follow-up visit. 
(specify reason for refusal: not contactable, out of study 
area, withdrew consent, died) 
 
Date of interview/ evaluation (DD/MON/YYYY) ____/_______/200____ 
Name of interviewer  
 
Clinical History since Study Day 540 
Symptoms Please circle one for 
each symptom 
Specify number of weeks 
Unexplained cough Y N  
Unexplained fever Y N  
Haemoptysis Y N  
Unexplained weight loss Y N  
Unexplained night sweats Y N  
Other (specify) Y N  
Other (specify) Y N  
If the participant has at least one symptom for two weeks or more or haemoptysis which is new or worsening 
since last contact, refer for TB investigation. 
 
Medical History / Hospitalisation since Study Day 540 
Has the participant had any significant illness or 
been hospitalized since the last study visit? 
Y N 
If yes, when? (month, year)  
 
















Study Day 720 
TB Contact History 
Has anyone with whom the participant is living with been 
diagnosed with TB since the last study visit? (please circle 
one) 
Y N Unk 
If so, who? (specify relationship to participant: father, 
mother, sibling, grandparent, aunt, uncle, cousin, friend, 
lodger) 
 
If yes, since when? (month, year)   
At what clinic? (specify the name of the clinic, or indicate 
‘Ukn’ if not known) 
 
If the subject has a new household TB contact since the last interview, refer for TB investigation. 
 
History of TB since Study Day 540 
Was participant investigated for TB since last study 
visit? 
Y N 
If yes, when? (DD/MON/YYYY) ____/_______/200____ 
If yes, by who? (specify the name of the clinic, or 
indicate ‘Ukn’ if not known) 
 
Was the participant put on TB treatment since the 
last study visit? 
Y N 
If yes, when? (DD/MON/YYYY) ____/_______/200____ 
If yes, at what clinic? (specify the name of the clinic, 
or indicate ‘Ukn’ if not known) 
 
If the participant is currently on TB treatment for TB or is under investigation for TB, the results of their 
investigations must be obtained. If any of the study procedures are not yet done, or if results are not available 
these procedures must be arranged (smears, cultures, chest x-ray and HIV test).  
















Study Day 720 
Study Examination and Tests 
Is TB investigation needed for: 
New household TB contact since last 
visit?? 
Yes No 
New or worsening symptoms? Yes No 
Being investigated for TB or on TB 
treatment 
Yes No 
If any of the above are answered “Yes”, then issue 2 sputum jars with instructions. 
Sputum jars issued Yes No 
















Clinical assessment if unable to produce 
sputum 
Not needed TB highly 
likely 
TB highly unlikely 
Referred for sputum induction Yes No 
Sputum induction performed Yes No 



















TB Investigation in between Visits (1) 
Reason for TB investigation between visits 










History of TB 
Date of interview ____/_______/200____ 
Was participant investigated for TB since last visit? Y N 
If yes, when? (DD/MON/YYYY) ____/_______/200____ 
If yes, by who?  
Was the participant put on TB treatment since last visit Y N 
If yes, when? (DD/MON/YYYY) ____/_______/200____ 
If yes, at what clinic?   
If the participant is currently on TB treatment for TB or is under investigation for TB, the results of their 
investigations must be obtained and any of the study procedures not yet done, must be arranged (smears, 
cultures, chest x-ray and HIV test). Two sputum samples for smear and culture must be taken. 
Study Examination and Tests 
Sputum jars issued Yes No 
Date sputum jars issued (DD/MON/YYYY) 1.____/_______/____ 
2.____/_______/____ 
Date of sputum jar collection (DD/MON/YYYY) 1.____/_______/____ 
2.____/_______/____ 








Clinical assessment if unable to produce sputum Not needed TB highly likely TB highly unlikely 
Referred for sputum induction Yes No 
Sputum induction performed Yes No 












TB Investigation in between Visits (2) 
Reason for TB investigation between visits 










History of TB 
Date of interview ____/_______/200____ 
Was participant investigated for TB since last visit? Y N 
If yes, when? (DD/MON/YYYY) ____/_______/200____ 
If yes, by who?  
Was the participant put on TB treatment since last 
visit 
Y N 
If yes, when? (DD/MON/YYYY) ____/_______/200____ 
If yes, at what clinic?   
If the participant is currently on TB treatment for TB or is under investigation for TB, the results of their 
investigations must be obtained and any of the study procedures not yet done, must be arranged (smears, 
cultures, chest x-ray and HIV test). Two sputum samples for smear and culture must be taken. 
Study Examination and Tests 
Sputum jars issued Yes No 
Date sputum jars issued (DD/MON/YYYY) 1.____/_______/____ 
2.____/_______/____ 
Date of sputum jar collection (DD/MON/YYYY) 1.____/_______/____ 
2.____/_______/____ 








Clinical assessment if unable to produce sputum Not needed TB highly likely TB highly unlikely 
Referred for sputum induction Yes No 
Sputum induction performed Yes No 












TB Investigation in between Visits (3) 
Reason for TB investigation between visits 










History of TB 
Date of interview ____/_______/200____ 
Was participant investigated for TB since last visit? Y N 
If yes, when? (DD/MON/YYYY) ____/_______/200____ 
If yes, by who?  
Was the participant put on TB treatment since last 
visit 
Y N 
If yes, when? (DD/MON/YYYY) ____/_______/200____ 
If yes, at what clinic?   
If the participant is currently on TB treatment for TB or is under investigation for TB, the results of their 
investigations must be obtained and any of the study procedures not yet done, must be arranged (smears, 
cultures, chest x-ray and HIV test). Two sputum samples for smear and culture must be taken. 
Study Examination and Tests 
Sputum jars issued Yes No 
Date sputum jars issued (DD/MON/YYYY) 1.____/_______/____ 
2.____/_______/____ 
Date of sputum jar collection (DD/MON/YYYY) 1.____/_______/____ 
2.____/_______/____ 








Clinical assessment if unable to produce sputum Not needed TB highly likely TB highly unlikely 
Referred for sputum induction Yes No 
Sputum induction performed Yes No 
















Sputum1  Normal/Induced 






Sputum2   Normal/Induced 






Chest x-ray   
___/_____/____ 
Description: 
Abnormal, consistent with TB 
Abnormal but not TB 
Normal 
Other 







Referred for TB treatment Yes No 
Clinic Name  
Rx started Yes No Rx name  
Rx start date (DD/MON/YYYY) ___/_____/____ Rx stop date 
(DD/MON/YYYY) 
___/_____/____ 


















Referred for other investigations and/or 
treatment 
Yes No 










































Sputum1  Normal/Induced 






Sputum2   Normal/Induced 






Chest x-ray   
___/_____/____ 
Description: 
Abnormal, consistent with TB 
Abnormal but not TB 
Normal 
Other 







Referred for TB treatment Yes No 
Clinic Name  
Rx started Yes No Rx name  
Rx start date 
(DD/MON/YYYY) 
___/_____/____ Rx stop date 
(DD/MON/YYYY) 
___/_____/____ 


















Referred for other investigations and/or treatment Yes No 









































Sputum1  Normal/Induced 






Sputum2   Normal/Induced 






Chest x-ray   
___/_____/____ 
Description 
Abnormal, consistent with TB 
Abnormal but not TB 
Normal 
Other 







Referred for TB treatment Yes No 
Clinic Name  
Rx started Yes No Rx name  




Rx stop date 
(DD/MON/YYYY) 
___/_____/____ 

















Referred for other investigations and/or 
treatment 
Yes No 








































Follow Up 720 Days Participant Status 
 
                Participant Status                          Completed   
(please check one box): 
             Lost to follow-up 
             Date of last contact: ___/_______/____  
               DD/MON/YYYY 
            Withdrew consent 
            Date of withdrawal: ___/_______/____  
              DD/MON/YYYY 
            Reason for withdrawal:______________________ 
     ____________________________________________ 
 
           Death 
     Date of death: ___/_______/____  
               DD/MON/YYYY 
           Please check one in each item 
           Death certificate obtained? Y N 
           Cause of death per death certificate: __________ 
           __________________________________________ 
     __________________________________________ 
           Verbal autopsy performed? Y N 
           Verbal autopsy results: _____________________ 
           __________________________________________ 
     _________________________________________ 
     _________________________________________ 
           Was TB the cause of death? Y N 
           Full autopsy performed? Y N 
           Full autopsy results: ________________________ 
           _________________________________________ 
     _________________________________________ 
     _________________________________________ 
           Was TB the cause of death? Y N 
           Directed limited autopsy performed? Y N 
           Directed limited autopsy results: ______________ 
           _________________________________________ 
     _________________________________________ 
     _________________________________________ 





















APPENDIX E: Withdrawal/Refusals Addendum 
 
Withdrawal/Refusals Record ACS Extension 
Participants and their parents must be assured of their right to refuse and their right to withdraw and 
that there will be NO consequences to them answering this question. The collection of this 
information is merely for us to find out how we can improve participation in the study.  
Assignment (please circle one):   QFT converter QFT non-converter 
 











Study Day 0  Study Day 180 Study Day 360 
Study Day 540 Study Day 720 Other: 
 
Date of refusal:  ____/_____/20___ 
 


















APPENDIX F: Medical History/Hospitalisations Addendum 
Medical History / Hospitalisation 
Has the participant had any significant illness or been 
hospitalized since the last study visit, including 
hospitalization(s) for acute illness(es)?  
Y N Unk 
If YES, please specify since which study visit.  
 











Other (specify):  




Other (specify):  




Other (specify):  
















APPENDIX G: TB FACT SHEET 
10 Facts About Tuberculosis 
1. 1.8 million people died from TB in 2007 worldwide. 
2. More than 9 million cases of TB were reported in 2007 worldwide. 
(1.37 million of these 9 million TB cases were HIV positive) 
3. South Africa is ranked 5th in the world for the number of TB cases. 
4. South Africa has the highest number of new TB cases in the world. 
5. 73% of TB cases in South Africa are HIV positive. 
6. TB kills more youths and adults than any other infectious disease. 
7. One third of the world’s population is currently infected with the TB Bacillus. 
8. TB is a contagious disease but only people that are sick with TB in the lungs are 
infectious (Pulmonary TB). 
9. TB spreads though the air when infectious people cough, spit, talk or sneeze. 
10. Left untreated, a person with active TB can infect between 10 and 15 people every 
year. 
 
These are the signs and symptoms you should look out for. If you experience any of them, 
you should consult the nursing sister or doctor at your nearest clinic: 
 Coughing for three weeks or more 
 Blood in sputum (Haemoptysis) 
 Unexplained night sweats for three weeks or more 
 Unexplained weight loss 
 Unexplained fever for more than three weeks 
 Unexplained loss of appetite 
 Unexplained shortness of breath 
 
Should you experience any of these symptoms please contact the SATVI office 
(023) 346 5400:  Sr. F Kafaar or Nurse M van Wyk 
 
The figures quoted above were taken from the latest WHO global TB report: 
 Global Tuberculosis Control 2009, Epidemiology Strategy and Financing, WHO 2009. 
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1. OBJECTIVES OF LITERATURE REVIEW 
The study to be reported on focuses on the predictive ability of a converted interferon 
gamma release assay (IGRA) for tuberculosis (TB) disease. To contextualize this study, this 
literature review aimed to examine the available literature on the problem of TB disease and 
latent TB infection (LTBI) globally, the role of the tuberculin skin test (TST) in diagnosing TB 
and how IGRAs equate to the TST. Specifically we looked at the diagnosis of TB disease 
using IGRAs, the interpretation of serial IGRA data with a focus on IGRA conversion, the 
prognosis of an IGRA conversion and its potential use as a predictive test for the 
development of active TB disease. 
2. SEARCH STRATEGY 
A search was conducted in PubMed for articles published in English, related to the 
detection and/or diagnosis of tuberculosis infection and disease, the use of IGRAs, as well as 
the occurrence, measurement and interpretation of IGRA conversion and how these 
compare to TSTs. The following search phrases were used and combined using the Boolean 
operator ‚AND‛: (1) interferon gamma release assay OR interferon-γ assay OR IGRA OR T-
cell assay; (2) tuberculosis OR TB OR tuberculous; (3) tuberculin skin test OR TST; (4) 
quantiFERON OR QFT (5) conversion OR IGRA conversion OR QFT conversion OR TST 
conversion (6) predictive value OR predictive test. The electronic literature search was 
supplemented by articles received from subscribing to an online TB diagnostics workgroup 
as well as checking the reference lists of articles selected for inclusion in this review. 
3. SUMMARY OF THE LITERATURE 
Tuberculosis was declared a global health emergency over fifteen years ago by the World 
Health Organisation (WHO), and it remains amongst the world’s most lethal infections 
causing more adult deaths than any other disease.1 It is estimated that one third of the 
world’s population is infected with Mycobacterium tuberculosis (Mtb), resulting in 9.4 million 
new cases of TB and 1.3 million deaths due to TB being reported in 2009.1 Despite effective 
treatment regimens being available worldwide, the chronic nature of the disease as well as 
the increasing emergence of Mtb strains that are resistant to the currently available 












produced by the Stop TB Partnership (WHO) states that new technologies are required for 
optimal prevention, diagnosis and treatment for all forms of TB in people of all ages.2 They 
outline three strategies to combat TB: new diagnostics, new drugs and new vaccines. In the 
last five years, much progress in TB vaccine research has resulted in novel TB vaccine 
development and strengthening of the TB vaccine pipeline. Significant progress has also 
been observed in the development of new TB drugs, with at least eleven new or repurposed 
TB drugs currently under clinical investigation. However, minimal progress has been made 
in the development of new, more sensitive, simpler and cost effective diagnostic tools that 
will ultimately improve TB control as well as improve the quality of patient care.2  
The ‚gold standard‛ for TB disease identification is the growth by culture of Mtb from 
biological specimens. The WHO 2008 Global Tuberculosis Report highlights the lack of 
culture facilities in the government health sector in most devel ping countries. Sputum 
smear examination is the mainstay of diagnosis in such settings.3 Latent Tuberculosis 
Infection (LTBI) is defined as a positive TST result in an asymptomatic individual who has 
been exposed to TB and is showing no clinical or radiographic signs indicative of active TB 
disease.4  Five to 10% of those with LTBI will develop active TB disease during their lifetime 
(per year for HIV positive individuals) as a result of reactivation of the bacillus.5 The 
identification and treatment of LTBI to prevent progression to active TB disease thus 
remains a key method of helping to reduce the global TB burden. In developing countries, 
children under age 5 and HIV positive persons receive prophylactic treatment if diagnosed 
with LTBI. However, in developed countries where greater resources are available, a 
significantly larger number of persons diagnosed with LTBI receive prophylactic treatment.  
3.1. Tuberculin Skin Test 
The tuberculin skin test (TST) has been the standard test used for diagnosing LTBI for over 
100 years.6 The TST is dependent on a delayed hypersensitivity response to purified protein 
derivative (PPD) of Mtb. It is a relatively cheap test that requires no laboratory component. 
However, its known limitations are that the TST is confounded by non-tuberculous 












(BCG) vaccination, the method of test administration as well as the need for a second patient 
visit for the reading of results 48-96 hours post administration.7 
Although the TST has been used for many years, there are still aspects regarding the 
administration and interpretation of results that remain controversial. The use of repeated 
tuberculin tests have shown that tuberculin reactions may increase in size due to one of 
three reasons: random variability from differences in administration, reading of results, or 
biologic response; immunologic recall of preexisting delayed type hypersensitivity to 
mycobacterial antigens (boosting); or new infection (conversion). It has also been shown that 
tuberculin reactions may decrease in size (reversion).6 
Tuberculin conversion in general may be defined as ‘the development of new delayed type 
hypersensitivity to mycobacterial antigens following new infection with Mtb, NTMs or BCG 
vaccination.’6 Various studies report the occurrence of tuberculin conversion, as well as an 
association between conversion and the development of TB disease.8,9 Recent conversion is a 
known factor representing a higher risk for progression to TB disease compared to more 
remote infection. In a study of contacts of index cases with TB disease with documented 
tuberculin conversion, 7% developed active TB disease in the first year and an additional 
7.5% developed TB disease in the 3 year period that followed.8 Among a total of 29 000 
adolescents, in those randomised to not receive BCG vaccination in Britian, tuberculin 
conversion was observed in 2 170 (7.5%) during the 2 year follow up period. TB disease was 
observed in 5.2% of those who converted (80% of these within 2 years).9 
The booster phenomenon of an increased tuberculin reaction when retested within a short 
period of time without the presence of new infection results from the recall of waned cell-
mediated immunity. Boosting is associated with TB infection that is remote in time, NTM 
sensitization and BCG vaccination and thus appears to be a nonspecific response to any 
preceding mycobacterial exposure.6 Maximal boosting is observed if the interval between 
the first and second test is between 1 and 5 weeks but boosting can still be detected one or 
more years after a first negative tuberculin test.10 Boosting is best distinguished from 
conversion on clinical grounds. Boosting is said to have occured when an increase in 












exposed to Mtb. In contrast, conversion is said to have occurred when a previously TST-
negative individual tests positive after either receiving BCG vaccination or following 
exposure to Mtb.6 
Serial tuberculin testing has shown that tuberculin reversion may occur (ie. a decrease in 
tuberculin reaction size upon retesting). Various tuberculin reversion rates are reported for 
different studies with an increased occurrence in those in whom the boosting phenomenon 
has been identified.6,11 
3.2. Interferon-gamma Release Assays 
The recent identification of Mtb antigens absent from BCG and most NTMs has allowed for 
the development of more specific diagnostic tests than the TST. The interferon-gamma 
release assays (IGRAs) provide a new tool for the diagnosis of LTBI as well as for 
surveillance for new TB infections.12 These tests detect interferon-gamma (IFN – γ) released 
by T cells when exposed to Mtb antigens in vitro. The antigens used are the early secreted 
antigenic target 6 (ESAT-6) and the culture filtrate protein 10 (CFP-10). Operationally, 
IGRAs have several advantages over the TST: they are unaffected by prior BCG vaccination, 
the tests can be completed in one visit with the results available within 24 hours; they are 
able to avoid false positives due to repeat testing; and have a standardized interpretation.13 
Limitations of IGRAs include the high cost, need for equipped laboratories and trained 
personel, and like TST, they cannot distinguish between LTBI and active TB disease. 
There are two commercially available IGRAs that have been approved by the US Food and 
Drug Administration (FDA) that are in clinical use: the QuantiFERON-TB Gold (Cellestis®, 
Carnegie, Australia) and T-Spot.TB (Oxford Immunotec®, Oxford, United Kingdom).13 
There are also in-house developed versions in clinical use as well. The QuantiFERON Gold 
In-Tube (QFT-G IT) is a newer version of the QuantiFERON Gold (QFT-G). The QFT-G IT 
includes a third antigen, TB7.7 which is thought to enhance the sensitivity of the assay 
without reducing its specificity. In addition, QFT-G IT requires only 3mL of blood compared 
to the 16mL of the QFT-G assay. Both versions of QuantiFERON (QFT) are based on a 16-












based on an enzyme-linked immunospot assay (ELISPOT) that utilises peripheral blood 
mononuclear cells (PBMCs).14  
In theory, IGRAs have operational advantages that make them ideal for serial testing.15 
IGRAs may also have a potential use in providing a more accurate estimate of the annual 
risk of TB infection (ARTI) in specific populations.16  IGRAs have been recommended for 
serial testing in some countries but data is limited on the interpretation of repeat IGRA 
testing. There is evidence from existing studies17, although limited, that suggests 
conversions, reversions and non-specific variations occur with IGRA serial testing, as they 
do with the TST. However, there is still no consensus on how to define and/or interpret 
these conversions and reversions.13  
In order to interpret and utilise IGRAs in serial testing, data is required to answer several 
key questions15,16: (1) What is the reproducibility of T cell responses over time (within-
subject variations over time)? (2) What is an IGRA ‚conversion,‛ and what threshold (cut-
off) should be used to define conversion? How can IGRA conversions be distinguished from 
non-specific (random) variations in T cell responses over time? (3) What is the prognosis of 
an IGRA conversion? Are individuals with strong conversions (i.e large increases in IFN-γ 
responses over time) at higher risk of progression to active disease than individuals with 
weak conversions or negative results? (4) What is an IGRA ‚reversion,‛ and what threshold 
should be used to define reversion? What is the clinical significance and prognosis of an 
IGRA reversion? (5) Will treatment of individuals with IGRA conversions reduce their risk 
of progression to active TB disease? 
3.2.1. Within-Subject Variability of IGRAs 
According to a systematic review conducted by van Zyl-Smit et al. 2009, there is a lack of 
published, peer-reviewed IGRA reproducibility data. Although several studies have 
reported assessment of IGRA reproducibility, these have been done following tuberculin 
skin testing or in the context of contact screening and thus cannot be considered to be 
reproducibility studies.18 In a study carried out in India, in 14 health care workers (HCW), 
all BCG vaccinated, over a two week period, quantitative results showed a 16% increase of 












carried out in South Africa, in 26 HCW and low risk volunteers, all BCG vaccinated, over a 
period of three weeks; quantitative results showed that a  change of +/-80% of any given 
IFN-γ response (QFT-G IT) or +/-3 spots (T-SPOT.TB) was considered to fall within the 
‘normal’ expected within subject variability.20 Although these sample sizes are small, they 
show that within-subject variability in IGRA results does occur and is not inconsequential in 
high TB burden settings. Variability is also seen to be more frequent in individuals with 
baseline positive IGRA results, and in those results that are around the cut-off points.18 
3.2.2. IGRA Reversion 
In general, a reversion may be defined as an IGRA result that becomes negative upon repeat 
testing (ie. a decrease in IFN-γ responses). However, it remains unclear what threshold 
should be used to define reversion.15 Studies show that IGRA reversions are more likely 
when the baseline test results are discordant – positive IGRA but negative TST.17,21 There are 
several possible reasons why reversion occurs. Reversion might reflect clearing of TB 
infection, might be due to biological variations within IGRA positive individuals, or  due to 
variability in laboratory and test procedures.15 Hill et al. 2007 propose that IGRA responses 
are inherently transient and need continued exposure to TB antigens to maintain high 
frequencies. Thus, reversion could reflect a dormant stage in the Mtb life cycle where 
antigens such as ESAT-6 and CFP-10 are not reliably secreted.17  
The prognosis of an IGRA reversion remains unclear. Friedman et al. 2007 suggest that 
reversions are an indication of a lack of immunity to TB and that individuals with IGRA 
reversions should be retested when exposed again.22 
3.2.3. IGRA Conversion 
In general, a conversion may be defined as an IGRA result that becomes positive upon 
repeat testing (ie. an increase in IFN-γ responses) following a new infection with Mtb.15 
Despite high IGRA conversion rates having been reported in high-risk populations in TB 
high burden settings13,23, there is still no consensus on how to define and interpret these 
conversions. Uncertainty remains on how much increase in IFN-γ response is an indication 












evidence to support the view that if a simplistic negative-to-positive cut-off is used to define 
conversions, IGRA conversion rates may be higher than those observed with TST.13,23 
In a cohort study conducted in rural India, where the occurrence of conversions and 
reversions were investigated among 250 TB contacts; the effect of using various definitions 
and criteria for conversion was evaluated. They evaluated two definitions for TST 
conversion and four definitions for QFT conversion. Among 11 contacts with baseline TST-
positive/QFT-negative results, four (36%) were reported to have converted using a simple 
negative-to-positive definition. Among the 85 contacts reported to have had baseline TST-
negative/QFT-negative results, the estimated rates of QFT conversions (using four different 
definitions) ranged between 11.8% and 21.2%. The highest conversion rate of 21.2% (95% CI 
13-31) was estimated using the least stringent definition of negative to positive [baseline 
IFN-γ <0.35 IU/ml and follow-up ≥0.35 IU/ml+; while the lowest conversion rate of 11.8% 
(95% CI 6-20) was estimated using the most stringent definition of an increase from baseline 
IFN-γ <0.35 IU/ml to ≥0.70 IU/ml. Although not statistically significant, there was nearly a 
two-fold difference between the most and least stringent definition for QFT conversion. In 
contrast, the estimated TST conversion rates ranged between 7.5% and 13.8%. With the most 
stringent definition for TST conversion [baseline TST <10mm and follow-up TST ≥10mm, 
with 10mm increment], the conversion rate was 7.5% (95% CI 3-16); while a conversion rate 
of 13.8% was observed with the least stringent definition [baseline TST <10mm and follow-
up TST ≥10mm, with 6mm increment]. Although not statistically significant, the TST 
conversion rate with the most stringent definition is about three-fold lower than the QFT 
conversion rate estimated with the least stringent definition.13                                                                              
The observed higher conversion rate of IGRAs when compared to TST could possibly 
indicate an increased sensitivity for conversions (not necessarily for the diagnosis of LTBI). 
A proportion of this higher sensitivity is probably a result of minor non-specific variations 
around the diagnostic cut-off; where a more stringent cut-off for conversion may reduce 
misclassification of minor variations as conversions.15, 13 With regard to TST, Menzies (2000) 
states that variability in biologic response and differences in test administration and reading 
will result in increases of less than 6mm in 95% of subjects. Thus, an increase of 6mm or 












biological change (conversion or boosting).6 Using a stringent cut-off to define IGRA 
conversion would be comparable to the TST threshold for conversion, which requires a 
6mm increase in size of induration above the baseline value to an induration of at least 
10mm.15,6 
In a previous study, Harada et al. 2004 recommended the use of a ‘grey zone’ when 
analysing QFT results (0.10-0.35 IU/ml), suggesting that results in this grey zone should be 
excluded from conversion rate calculations.24 Pai et al. 2009 also explored the use of a ‘zone 
of uncertainty’ on either side of the existing QFT cut-off (0.35 IU/ml). They chose 0.20-0.50 
IU/ml as the uncertainty zone; where any value <0.20 IU/ml was considered ‘definitely 
negative’ and any value > 0.50 IU/ml was considered ‘definitely positive’. A person was 
considered to have a ‘true conversion’ if their IFN-γ result increased from <0.20 IU/ml at 
baseline to >0.50 IU/ml on the repeat test. Among the 18 contacts who had QFT conversion 
using the least stringent definition [baseline IFN-γ <0.35 IU/ml and follow-up ≥0.35 IU/ml+, 
the uncertainty zone analysis suggested that ‘true conversions’ occurred in 9/18 (50%).13  
3.2.4. What is the predictive value of an IGRA conversion? 
An established risk of developing active TB disease is associated with TST conversions.25 
Clinical trials have confirmed that the treatment of people who are TST positive reduces 
their risk of progression to active TB disease, and as a result guidelines for targeted TST 
testing and treatment have been established.26 If IGRAs were found to have the same (or 
better) sensitivity of predicting the development of active TB disease as TST, it would 
minimize the rates of false-positive responses in contacts of TB cases meaning fewer people 
being assessed for TB disease and put on chemoprophylactic treatment. In the developing 
world, this could aid in focusing scarce TB-control and treatment resources only on those 
individuals identified to have the highest risk of developing active TB disease.27  
There seems to be a growing consensus that a positive IGRA is a more specific indicator of 
the presence of LTBI than TST, and that it might be a better predictor of those individuals 
who will rapidly progress to TB disease. Several studies support a higher rate of progression 












positive27-30; while several other studies report the predictive values of QFT and T.SPOT.TB 
for the progression to TB disease to be comparable to that of TST.31-34 
With limited data available, much uncertainty remains with regards to defining IGRA 
conversion and ultimately the risk of developing active TB disease that is associated with 
IGRA conversion. Conversion is indicative of recent infection, and the prognosis of new 
(recent) infection is expected to be different from that of more remote infection. In addition, 
the risk of developing active TB disease following a ‘strong conversion’ might differ from 
that of a ‘weak conversion’.15 Although there is no data to directly assess the prognosis of 
IGRA conversions, recent studies provide evidence that suggests that responses to ESAT-6 
and CFP-10 are closely associated with bacterial replication in vivo as well as with the 
progression from TB infection to TB disease.16,35 Andersen et al. 2007 hypothesized that high 
and/or rising levels of IFN-γ produced in response to ESAT-6 by T cells from recently TB-
infected people may signal early disease and could possibly be used as a prognostic marker 
for the development of clinical TB disease.35 If confirmed in large prospective cohort studies, 
the quantitative IFN-γ level could allow for the identification of a subgroup of individuals 
who may be in the process of developing TB disease15; providing a means by which to 
establish which individuals with LTBI should be treated first to prevent the development of 
TB disease. 
4. NEED FOR FURTHER RESEARCH 
In order to obtain data that will directly answer the questions of defining IGRA conversion 
as well as the prognosis of an IGRA conversion, prospective cohort studies need to be 
conducted that explore varying definitions for conversion and follow individuals from the 
time of conversion to document the incidence of TB disease in the years that follow, as well 
as to allow for the calculation of the time taken to develop TB disease following an IGRA 
conversion. Such studies would also allow for the assessment of the effect of using varying 
definitions for IGRA conversion on the calculation of the annual incidence of conversion as 













5. CONTRIBUTION OF DISSERTATION TO AVAILABLE LITERATURE 
The proposed study was an extension of a prospective epidemiological study of TB disease 
and infection in adolescents in the Worcester and surrounding areas in the Western Cape 
carried out from 2005 to 2009, from which a subset of adolescents who were identified to 
have converted their IGRA (QFT) status were followed up and observed for the occurrence 
of active TB disease. The results of this study will contribute to the very limited available 
literature on IGRA conversion by providing the first measure (to our knowledge) of the 
incidence rate of active TB disease following an IGRA conversion. In addition, the results 
will also provide insight on whether IGRA conversion is predictive for the development of 
active TB disease (in comparison to individuals without IGRA conversion); as well as assess 
the effect of varying the definition of conversion on the incidence rates of active TB disease 
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 ABSTRACT  
Rationale: Conversions and reversions occur with interferon-gamma release assay (IGRA) 
serial testing, as with the tuberculin skin test (TST). An established risk of developing 
tuberculosis disease (TB) is associated with TST conversions. This risk in those with a 
converted IGRA status is unknown. 
Objectives: To evaluate the incidence rate of active tuberculosis disease following 
QuantiFERON TB Gold In-Tube (QFT-IT) conversion compared to non converters. 
Methods: From a parent cohort study, adolescents identified as having a converted IGRA 
status (QFT Converters [n=534]) were followed up for 2 to 4 years and observed for 
incident tuberculosis disease and compared to adolescents whose IGRA status remained 
negative throughout (QFT Non-Converters [n=629]).  
Measurements and Main Results: For QFT Converters, the tuberculosis incidence rate (all 
cases) was 1.2 cases per 100 person years (95% CI 0.66-1.94); cumulative incidence 2.8% 
(95% CI 1.58-4.59) mean 2.4 years of follow up. 13/15(87%) incident cases developed 
tuberculosis disease within 2 years following QFT conversion. A significantly lower 
tuberculosis incidence rate (0.17 cases per 100 person years [95% CI 0.02-0.62]) and 
cumulative incidence (0.32% [95% CI 0.03-1.14]) was observed for QFT Non-Converters. 
The incidence rate ratio was 6.9 (95% CI 1.9-24.6) for all cases TB and 7.4 (95% CI 1.3-43.3) 
for per protocol TB. 
Conclusion: QFT conversion is indicative of an approximately 7-fold higher risk of 
progression to TB disease (compared to non-converters) in a cohort of adolescents in a high 
TB burden population. Further studies in high and low TB burden settings are required to 
validate these findings.  













Interferon-gamma release assays (IGRAs) provide a new tool for the diagnosis of latent 
tuberculosis infection (LTBI).1 IGRAs are blood tests that detect interferon-gamma (IFN-γ) 
released by T-cells on exposure to Mycobacterium tuberculosis (Mtb) antigens. These antigens 
are more specific to Mtb than the purified protein derivative (PPD) used in the tuberculin 
skin test (TST).2,3,4  
IGRAs have been recommended for serial testing for tuberculosis (TB) infection in 
populations with continued risk of TB exposure.5 In low TB incidence countries initial 
testing with TST followed by IGRAs to confirm positive TST results or use of IGRAs as an 
alternative to TST has recently been recommended.2,6,7 IGRAs have features that make them 
ideal for serial testing: they are unaffected by prior Bacilli Calmette Guérin (BCG) 
vaccination, they are ex-vivo assays that can be completed in one visit, they can be repeated 
without sensitization or boosting, they have a standardized interpretation, and there is  
evidence that suggests  IGRAs may be  better than TST at detecting recent rather than 
remote TB infection.8-10 Although limited, data from existing studies shows that 
conversions, reversions and non-specific variations occur with IGRA serial testing as they 
do with TST serial testing.10-13   
Several reviews indicate that in order to utilize IGRAs in serial testing, evidence is still 
required to answer several key questions that include8,9,3: (a) What is an IGRA ‚conversion‛ 
and what threshold  should be used to define conversion? (b) What is the prognosis of an 
IGRA conversion? (c) What is an IGRA ‚reversion,‛ and what threshold should be used to 
define reversion?  
An established risk of developing active TB disease is associated with TST conversions.14 
The risk in those with a converted IGRA status remains unknown. IGRA conversion is 
indicative of recent infection, and the prognosis of new (recent) infection is expected to be 
different from more remote infection.8 
In the present study we report the first measure (to our knowledge), of the TB incidence 












rate of active TB disease following QuantiFERON Gold In-Tube (QFT-IT) conversion and to 
assess the predictive value of QFT-IT conversion for the development of active TB disease. 
We also assessed the effect of varying the definition of QFT-IT conversion on the TB 
incidence rate. The study was conducted in Worcester, a small town in the Western Cape 
Province of South Africa with an estimated population of 151 80615 and a TB incidence rate 
of 1400/100 000 reported in 2006.16  
METHODS 
Study Design  
The study reported here is a prospective observational cohort study with no experimental 
interventions. It was conducted as an extension of a prospective epidemiological cohort 
study of TB disease and infection in adolescents (aged 12 to 18 at time of enrolment into 
parent cohort study) in Worcester and its surrounding areas in the Western Cape, South 
Africa.17 Participants from both the active and passive follow up strategies of the parent 
cohort study17 whose QFT-G IT test status converted from having been negative at baseline 
to being positive at a subsequent time point (QFT Converters at 6, 12, 18 or 24 months) 
were followed up for a further two years after their 2-year study visit of the parent study 
and observed for the development of active TB disease. This led to a maximum of up to 4 
years post conversion follow up. A similar sized, randomly sampled control group of 
participants who remained QFT-G IT negative throughout the parent cohort study (QFT 
Non-Converters) underwent similar follow-up. The cohort resulting from these two 
subgroups (QFT Converters and QFT Non-Converters) was observed further from March 
2009 until September 2010. Thus, observation time for all participants is measured 
beginning from 2-year visit of the parent cohort study, and continued until the last study 
visit in the subsequent study reported here. Participants from both study groups were seen 
at six monthly intervals and interviewed about: new TB symptoms; new household 
contacts; being screened for TB and/or diagnosed with TB since the last study visit. As with 
the parent cohort study17, hospital admission and mortality surveillance were conducted 
for all participants. The study was approved by the Faculty of Health Sciences Human 












obtained from participants >18 years; while participant assent and parental consent were 
obtained for those <18 years.  
TB Diagnosis and Diagnostic Processes 
A case of TB was defined as any case that was diagnosed by a physician and confirmed by 
two or more sputum smears positive for acid fast bacilli (AFB) and/or one positive sputum 
culture for Mtb.  Participants suspected of having TB were investigated through sputum 
tests and/ or chest x-rays. In the case of negative sputum smears and cultures, or in the 
absence of these tests, TB diagnosis by physicians was based on chest x-rays and clinical 
symptoms. 
Definitions of Conversion and Reversion 
We explored four definitions for QFT conversion based on the definitions reported by Pai 
et al. (2009)10:                                                                                                                                                      
(1) baseline IFN-γ <0.35 IU/ml and follow up IFN-γ ≥ 0.35 IU/ml;5                                                  
(2) baseline IFN-γ <0.35 IU/ml and follow up IFN-γ ≥ 0.35 IU/ml, plus a 30% increase in 
IFN-γ over the baseline value;18                                                                                                                          
(3) baseline IFN-γ <0.35 IU/ml and follow up IFN-γ ≥ 0.35 IU/ml, plus an absolute increase 
of 0.35 IU/ml over the baseline value;11 and                                                                                              
(4) baseline IFN-γ <0.35 IU/ml and follow up IFN-γ ≥ 0.70 IU/ml.11                                              
Only one definition was explored for QFT reversions: baseline IFN-γ ≥ 0.35 IU/ml and 
follow up IFN-γ < 0.35 IU/ml.10  
Uncertainty Zone Analysis 
Some studies have reported a ‘zone of uncertainty’ regarding QFT conversion, where 
values falling in this zone might not be ‘true conversions’.19,10 We explored an uncertainty 
zone of 0.20 UL/ml-0.50 UL/ml as described by Pai et al. (2009) and any QFT results falling 














All data was captured in a Microsoft Access database. Categorical data was compared 
between the two study groups using the Pearson’s χ2 test. The two sample t-test was 
performed to assess whether there was a difference in the distribution of continuous 
variables between the two study groups. The cumulative incidence for TB disease for each 
study group is reported with the 95% confidence interval (CI). TB incidence rates were 
calculated for the two study groups and the different QFT conversion definitions. TB 
incidence rates are reported per 100 person time years of observation and the 95% CI are 
given for each rate. Observation time was calculated from the participants 2-year (24 
month) study visit in the parent cohort study for both QFT Converters and QFT Non-
Converters.  Survival analysis was conducted to compare Kaplan-Meier survival estimates 
for the time taken to develop TB disease for the two study groups. Cox proportional 
hazards regression was conducted in order to assess if there was an association between 
baseline characteristics and the risk of developing TB disease. Statistical analyses were 
performed using STATA/IC 10 (Stata Corp, College Station, TX, USA) software. 
 
RESULTS 
Study Participants  
The selection of study participants is set out in Figure 1. From May 2005 to February 2009, a 
total of 6363 adolescent participants were enrolled into the parent cohort study and 
followed up using either active or passive follow up strategies17; with participants in either 
follow up strategy receiving at least a baseline QFT and a follow up QFT at 24 months. 
From these participants, a total of 798 participants were identified to have a converted QFT 
status (baseline negative IFN-γ <0.35 IU/ml and follow up positive IFN-γ ≥ 0.35 IU/ml at 6, 
12, 18 or 24 months) on repeat testing. All contactable QFT converter participants were 
approached and consent for further follow up was obtained if they were willing to 
participate. Consent for continued follow up from March 2009 was obtained from 675 
participants. An additional 8 participants were identified to have developed TB disease 












they were included in the analysis as cases. From these 683 QFT Converters (675 + 8), only 
534 (baseline negative IFN-γ <0.35 IU/ml and follow up positive IFN-γ ≥ 0.35 IU/ml at 24 
months) were selected for inclusion in the analysis presented here.  This was done in order 
to standardize the conversion point used by restricting the analysis only to those who 
converted at 24 months.                                                                                              From the 
parent cohort, a total of 1993 QFT Non-Converters were identified. These were participants 
whose QFT status remained negative throughout the study (baseline negative IFN-γ <0.35 
IU/ml and follow up negative IFN-γ <0.35 IU/ml at 6, 12, 18 and 24 months). A random 
sample of these was selected for continued follow up from March 2009 and 629 QFT Non-
Converters were subsequently consented and included in the analysis presented here.                                                
The mean follow up time for the QFT Converter group was 2.4 years (ra ge 0.3 months to 
48 months). The mean follow up time for the QFT Non-Converter group was 1.9 years 
(range 10 months to 37 months).      
The baseline characteristics of the selected participants are shown per study group in Table 
1. There was no significant difference between the two study groups regarding sex and 
employment status. Although the mean age at consent for continued follow up in this 
study for the two groups were similar - 18.71 years for QFT Converters and 18.48 years for 
QFT Non-Converters; the difference was found to be significant (p=0.01). There were also 
small but significant differences between the two study groups with respect to school 
attendance, BCG scar, ethnicity and income.  
TB Incidence Rates and Cumulative Incidence by QFT group 
15 participants in the QFT Converter group were diagnosed with TB, of whom 8 met the 
protocol case definition and 7/8 being culture positive. Two participants in the QFT Non-
Converter group were diagnosed with TB, with one meeting the protocol case definition 
and being culture positive. The overall TB incidence rates and cumulative incidence by 
QFT group are shown in Table 2a. The TB incidence rate (all cases) for the QFT Converter 
group was 1.2 cases per 100 person years (95% CI 0.66-1.94) and the cumulative incidence 
was 2.8% (95% CI 1.58-4.59) over the 2.4 mean years of follow up. 13/15(87%) of the QFT 












The positive predictive value of QFT conversion for development of active TB disease 
within 2 years following conversion is 2.4% (13/534). The incidence rate (all cases) for the 
QFT Non-Converter group was 0.17 cases per 100 person years (95% CI 0.02-0.62) and the 
cumulative incidence was 0.32% (95% CI 0.03-1.14) over the 1.9 median years of follow up. 
Both QFT Non-Converter incident cases occurred within 2 years of follow up. The 
incidence rate ratio (IRR) was 6.9 (95% CI 1.9-24.6). 
Per protocol analysis of TB Incidence Rates and Cumulative Incidence by QFT group 
Using only the incident cases meeting the protocol TB case definition, both the incidence 
rates and cumulative incidence for both study groups were halved (Table 2b). The 
incidence rate ratio was 7.4 (95% CI 1.3-43.3). 
Survival Analysis 
Survival analysis showed a significant difference in Kaplan-Meier survival estimates for the 
time taken to develop TB disease for QFT Converters when compared to QFT Non-
Converters (Log Rank test: χ2=9.45; p=0.002). Cox proportional hazards regression revealed 
that other than the QFT conversion status [univariate analysis: hazard ratio (hr)=7.35; 
p=0.009], none of the variables assessed at baseline (Table 1) had a significant effect on the 
risk of developing TB disease.  
Annual Incidence Rates in years following QFT conversion 
A further analysis was conducted to assess the annual TB incidence rates in the years 
following QFT conversion. These incidence rates are shown in Table 3. In the first to the 
fourth year following QFT conversion, TB incidence rates were 1.7, 0.84, 0 and 4.8 per 100 
person years respectively, with no significant difference being observed.  Most cases, 9/15 
(60%) occurred within the first year following QFT conversion. A much smaller number of 















The effect of varying the definition of QFT Conversion on the TB Incidence Rate 
Among the 534 QFT Converters, the TB incidence rate using the four different QFT 
conversion definitions ranged between 1.20 and 1.34 per 100 person years. The number of 
participants, the number of incident cases that met the criteria for each QFT conversion 
definition as well as the incidence rate for each are shown in Table 4. The TB incidence 
rates were very similar across the four QFT conversion definitions with no significant 
differences observed. 
Uncertainty Zone Analysis 
Among the QFT Converters defined using the least stringent definition, 116/534 (21.7%) fell 
into the uncertainty zone [0.20 UL/ml-0.50 UL/ml]. These included 4/15(26.7%) of the 
incident cases. This analysis suggests that ‘true conversion’ *a change from <0.20 UL/ml to > 
0.50 UL/ml] occurred in 418/534 (78.3%) QFT Converters and this included 11/15 (73.3%) of 
the incident cases. This results in a cumulative incidence of 2.6% (11/418). 
Incidence of QFT Reversions 
Participants with QFT reversions were not included in the analysis presented here. 
However, using a simple positive to negative definition for reversion [baseline IFN-γ ≥ 0.35 
IU/ml and follow up IFN-γ < 0.35 IU/ml+ we were able to identify 241/6363 (4.1%) QFT 
reversions in the parent cohort study. There were no incident cases amongst the QFT 
reverters. 
DISCUSSION 
This study provides the first measure (to our knowledge) of the incidence rate of active TB 
disease following an IGRA (QFT) conversion as well as its predictive value for the 
development of active TB disease. QFT Converters are shown to have a higher risk of 
developing TB disease when compared to QFT Non-Converters. Survival analysis revealed 
a significant difference in the time taken to develop TB disease between the QFT 
Converters and QFT Non-Converters. QFT Converters were shown to have a 7-fold 












Converters [hr=7.35; p=0.009]. The positive predictive value of QFT conversion for the 
development of active TB disease is 2.4% within 2 years following QFT conversion. 
Varying the definition of QFT conversion did not significantly affect the TB incidence rate. 
The identification and treatment of latent tuberculosis infection (LTBI) to prevent 
progression to active TB disease remains a key method of helping to reduce the global TB 
burden (mostly in developed countries at this stage). The rationale for this being that 
treating LTBI will decrease the incidence of TB disease and consequently reduce the 
transmission of Mtb. However, the question remains as to which individuals with LTBI 
present the highest risk of progression to TB disease. The predictive value of positive 
IGRAs compared to TST for the development of TB disease has been evaluated in several 
studies, with inconsistent results of  progression to TB disease in those who are QFT 
positive compared to those who are TST positive.20-24 In contrast, several other studies 
(including the parent cohort study17) report the predictive values of QFT and T.SPOT.TB 
for the progression to TB disease to be comparable to that of TST.11,25-27 A known risk of 
developing active TB disease is associated with TST conversions.28 Clinical trials have 
confirmed that the treatment of people who are TST positive reduces their risk of 
progression to active TB disease, and as a result guidelines for targeted TST testing and 
treatment have been established.29 If IGRAs were found to have the same (or better) 
sensitivity of predicting the development of active TB disease as TST, it would minimize 
the rates of false-positive responses in contacts of TB cases meaning fewer people being 
assessed for TB disease and put on preventative treatment. In the developing world, this 
could aid in focusing limited TB-control and treatment resources only on those individuals 
identified to have the highest risk of developing active TB disease.20  
The results of this study show that the risk of developing TB disease is significantly higher 
in QFT Converters when compared to QFT Non-Converters. At baseline, some small but 
significant differences in demographic characteristics were observed between the two 
study groups and these differences could be said to have influenced the difference in 
‘survival’ between the two study groups. However, following survival analysis, cox 












development of TB disease was the QFT group. A lack of significant risk factors other than 
QFT conversion may have been due to the small sample size.  
The results of this study regarding the predictive value of IGRA (QFT) conversion for the 
development of TB disease are in line with those reported for tuberculin conversion and its 
association with the development of TB disease.30 Recent conversion is a known factor 
representing a higher risk for progression to TB disease compared to more remote 
infection. Among a total of 29 000 adolescents, in those randomised to not receive BCG 
vaccination in Britain in 1966, tuberculin conversion was observed in 2 170 (7.5%) during 
the 2 year follow up period. TB disease was observed in 5.2% of those who converted (80% 
of these within 2 years).30 While our sample size was much smaller, the results of our study 
show that from a total of 6363 adolescents followed up in a cohort study, QFT conversion 
was observed in 798 (12.5%) during the two years of foll w up. In this analysis 
534/798(67%) QFT Converters were assessed further for the development of TB disease. Of 
these, 15(2.8%) were diagnosed with TB disease (87% of these within 2 years following QFT 
conversion). Although our study reports a higher conversion rate (which is probably due to 
the higher TB incidence in the area), we report a lower TB disease rate. This may be due to 
our selection method: we only included converters who had a negative baseline QFT and a 
positive QFT at 24 months. Thus, some of the TB cases may have occurred between 0 
(baseline)-24 months of the parent cohort study, but we could not include them in the 
analysis for correct comparison with the QFT Non-Converter group. 
Our results suggest that 100 people identified to have converted their QFT status would 
require treatment to prevent 2-3 TB cases in a period of 2 years. However, the numbers 
based on these results are too low to warrant preventive therapy. The cost effectiveness of 
such preventive measures within a high TB burden setting such as ours, where resources 
are very limited, and re-infection is common, would have to be evaluated. Thus, at this 
stage the findings of this study might be of more relevance to low TB burden countries 
where many/most infected individuals receive preventive therapy. 
We explored the effect of varying the definition of QFT conversion (as described 












study was that varying the definition of QFT conversion had very little impact on the TB 
incidence rate with the least stringent and most stringent definitions reporting very similar 
incidence rates. In addition, 14/15(93%) incident cases met the criteria for the most stringent 
definition suggesting that a considerable change in the quantitative measure of IFN-γ  is 
observed for QFT converters who subsequently develop TB disease. Application of an 
‘uncertainty zone’ showed 78% (with 11/15 (73%) incident cases) of QFT conversions to be 
‘true conversions’; resulting in a very similar cumulative incidence. Our results suggest 
that application of this zone results in fewer converters and fewer TB cases, but hardly 
affects the TB incidence rate. The use of such a zone would have to be explored further.  
There were several limitations to the analysis presented here. The absolute number of QFT 
Converters identified from the parent cohort study was relatively small. Due to the 
structure of the parent cohort, the number of QFT Converters subsequently used in the 
analysis was even smaller suggesting that the TB incidence rate in the QFT Converter 
group was an underestimate.  The intended extended follow up period was at least 2 years 
post QFT conversion, but a considerable number 175/534 (33%) of QFT Converters had an 
extended follow up period of < 2years post conversion due to premature termination of the 
study because of financial constraints. Several incident cases might have been missed as a 
result of this shortened observation time. Investigation and diagnosis of participants were 
partly dependent on public health services and not all test results were made available to 
study staff. This could possibly have had a negative impact on the per protocol analysis of 
the TB incidence rates. HIV status was not determined in this study except that all those 
diagnosed with TB were offered an HIV test. However, background HIV prevalence is 
relatively low in this community and HIV status was not expected to influence the results 
of this study. 
We conclude that QFT conversion is indicative of an approximately 7-fold higher risk of 
progression to TB disease (compared to non-converters), in a cohort of adolescents in a 
high TB burden population. The predictive value of QFT conversion for the development 
of active TB disease is 2.4% within 2 years following QFT conversion. Varying the 
definition of QFT conversion seems to have minimal effect on the TB incidence rate. More 












sizes and longer follow up periods are required to further validate our findings so as to 
establish an optimum definition for QFT conversion, the clinical outcome for those 
identified to have converted and the predictive value of a QFT conversion for the 
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Figure 1. Flow diagram showing selection of participants 
 
*
QFT=QuantiFERON; IFN-γ=interferon gamma; LTFU=loss to follow up 
** Observation time was calculated from the participants 2-year (24 months) study visit for both QFT Converters 





INCLUDED in present analysis: 
Random sample of QFT Non-Converters at 24 months** 
(n=629) 
All QFT Converters 
(Baseline –ve; Follow up +ve at 6, 12, 18 or 24 months) 
[Baseline IFN-γ <0.35 IU/ml and Follow up IFN-γ ≥ 0.35 IU/ml+ 
(n=798) 
INCLUDED in present analysis: 
Only QFT Converters at 24months** 
(n=534) 
All QFT Non-Converters 
(Baseline –ve; Follow up -ve at 6, 12, 18 and 24 months) 
 [Baseline IFN-γ <0.35 IU/ml and follow up IFN-γ < 0.35 IU/ml+ 
(n=1993) 
Total number of participants enrolled into 
parent cohort study17; depending on follow 
up strategy (active vs. passive) all 
participants received at least a baseline QFT 
and a follow up QFT at 24 months. 
(n=6363) 
EXCLUDED from present analysis: 
QFT Converters at 6, 12 or 18months 
(n=149) 
Participants not relevant 
to present study: 
(n=3572) 
QFT Converters included in       
present study: 
 (n=683) 
QFT Converters excluded from 
present study for reasons: LTFU, 
death, consent withdrawn, 












Table 1. Baseline Demographic Profile 
Variable n  
QFT Converter  
n (column %) 
QFT Non-Converter       
n (column %) p 
No. of participants 1163 534 629 
 Sex 
      Male 514 233 (44) 281 (45) 0.72 
  Female 649 301 (56) 348 (55) 
 School 
      In 638 274 (51) 364 (58) 0.03 
  Out 525 260 (49) 265 (42) 
 Ethnicity 
      Black 188 98 (18) 90 (14) <0.001 
  Coloured 878 427 (80) 451 (72) 
   White/Indian 97 8 (2) 86 (14) 
 Employment status 
      Employed 277 138 (26) 139 (22) 0.14 
  Unemployed 886 396 (74) 490 (78) 
 BCG scar 
      Present 494 257 (48) 237 (38) 0.001 
  Absent 299 119 (22) 180 (29) 
   Not sure 370 158 (30) 212 (33) 
 Income 
      R1-R1000 89 56 (11) 33 (5) 0.004 
  R1001-R4000 104 53 (10) 51 (8) 
   None 1000 425 (79) 545 (87)   
     **Average Age (SD) 
 
18.7(1.4) yrs 18.5(1.5) yrs 0.01 
*QFT=QuantiFERON; BCG=Bacille Calmette Guerin; yrs=years 






















Table 2a. Overall TB Incidence and Cumulative Incidence by QFT group (all cases TB) 







Incidence Rate              
per 100pyrs 
 (95% CI) 
Cummulative 
Incidence         
(95% CI) 
QFT +ve 534 15 1268 1.2 (0.66-1.94) 2.8% (1.58-4.59) 
      QFT -ve 629 2 1169 0.17 (0.02-0.62) 0.32% (0.03-1.14)  
            



































Table 2b. Overall TB Incidence and Cumulative Incidence by QFT group (PP TB cases) 






Incidence Rate              
per 100pyrs 
 (95% CI) 
Cummulative 
Incidence         
(95% CI) 
QFT +ve 534 8 1268 0.6 (0.27-1.24) 1.4% (0.65-2.93) 
      QFT -ve 629 1 1169 0.08 (0.002-0.48) 0.16% (0.004-0.88)  
            


































Table 3.  Annual Incidence Rates in years following QFT conversion. 













(per 100 pyrs) 95% CI 
Year 1 534 528 9 1.70 0.78-3.20 
Year 2 524 475 4 0.84 0.23-2.14 
Year 3 359 222 0 - - 
Year 4 113 41 2 4.8 0.58-16.16 

































Table 4. The Effect of varying the definition of QFT conversion on the TB Incidence Rate. 
Criteria for Defining QFT Conversion 
Number of 
participants 




Rate           
(per 100 pyrs) 95% CI 
1. Baseline IFN-γ <0.35, repeat IFN-γ ≥0.35 IU/ml 534 (100%) 15 1.20 0.66-1.94 
2. Baseline IFN-γ <0.35, repeat IFN-γ ≥0.35 IU/ml, plus 
30% increase over baseline value 514 (90.3%) 15 1.22 0.68-2.01 
3. Baseline IFN-γ <0.35, repeat IFN-γ ≥0.35 IU/ml, plus 
absolute increase of 0.35 IU/ml over baseline value 461 (80.7%) 15 1.34 0.75-2.20 
4. Baseline IFN-γ <0.35, repeat IFN-γ ≥0.70 IU/ml 461 (80.5%) 14 1.25 0.68-2.08 
*QFT=QuantiFERON; IFN-γ=interferon-gamma; TB=tuberculosis; CI=confidence interval; pyrs=person time 
years 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
